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‘You have to begin to lose your memory, if only in bits and pieces, to 
realise that memory is what makes our lives.  
 
Life without memory is no life at all, just as an intelligence without the 
possibility of expression is not really an intelligence.  
 
Our memory is our coherence, our reason, our feeling, even our action. 
Without it, we are nothing.’ 
 












                                                          
1 Buñuel, L. (1983). My Last Sigh (A. Israel, Trans.). New York: Knopf. 
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ABSTRACT: THESIS PORTFOLIO 
 
Background: Assessment of dementia in adults with intellectual disabilities 
poses specific challenges. Firstly, there is a paucity of validated, standardised 
and appropriate neuropsychological assessments of memory for adults with 
intellectual disabilities. Secondly, there are difficulties determining whether 
performance on neuropsychological assessments are attributable to pre-
existing intellectual disabilities, ‘normal’ ageing or part of a dementing 
process. A systematic review was therefore carried out to examine if there 
are memory changes associated with ‘normal’ ageing in the Down syndrome 
population. Following this an exploratory empirical research project was 
undertaken to examine one aspect of construct validity (i.e. convergent 
validity) of an associative memory test in a sample of adults with intellectual 
disabilities. This research project is presented as a journal article titled 
‘Convergent validity of the Visual Association Test (VAT) in adults with 
intellectual disabilities’. 
 
Methods: 40 participants aged between 18-45 years were recruited from 
Community Learning Disability Teams.  Participants completed the VAT and 
subtests of the modified Cambridge Cognitive Examination (CAMCOG-DS).  
IQ was assessed using the Wechsler Adult Intelligence Scale, Fourth Edition 
(WAIS-IV). Correlational analysis of the test variables were carried out. 
Participants with a diagnosis of dementia were excluded from the study. 
 
Results: All participants performed well on the VAT irrespective of age, 
gender or IQ. It was well received by participants. No significant correlations 
were found between the VAT and the subtests of the CAMCOG-DS or with 
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the subtests of the WAIS-IV. Therefore, there was no evidence of convergent 
validity with this test in this sample of participants.   
 
Conclusions: While the VAT was found to be an easy, quick test to use with 
people with intellectual disabilities and all participants scored above ‘floor’ 
level, it was not found to have convergent validity with the CAMCOG-DS. 
Further research is needed to determine if the VAT represents a useful tool 
for assessment with this population.  
 
Keywords: ageing, Down syndrome, intellectual disabilities, memory, 










































CHAPTER 1: SYSTEMATIC REVIEW 
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Running head: MEMORY CHANGE WITH ‘NORMAL’ AGEING IN DS 
 




Abstract: Systematic Review 
 
Aim: This review aimed to advance our knowledge and understanding of 
memory changes associated with ‘normal’ ageing in adults with Down 
syndrome.  
 
Methods: A literature search was conducted using various search engines 
including: MEDLINE, EMBASE, CINAHL, PsycINFO, ASSIA, Web of 
Science and Google Scholar, from the dates from which the databases began 
till July 2012. Inclusion and exclusion criteria are described. Quality of 
studies was assessed using the Scottish Intercollegiate Guidelines Network 
(SIGN) methodology checklist.   
 
Results: The search identified eight studies. There were four longitudinal 
studies and four cross-sectional studies. There were some indications of 
changes in memory associated with ‘normal’ ageing. However, due to the 
significant methodological limitations, further research is needed to 
substantiate this.  
 
Conclusion: There is a lack of rigorous empirical research examining 
memory associated with ‘normal’ ageing in adults with Down syndrome. 
Further research employing longitudinal designs are essential in order to 
evidence the ‘normal’ trajectory of memory abilities with age in this 
population.  
 





It is well acknowledged that adults with Down syndrome (DS) are more 
likely to develop Alzheimer’s disease (AD) than the general adult 
population, and at a much earlier age (British Psychological Society & Royal 
College of Psychiatrists, 2009). Over the last 30 years, there has been an 
increasing amount of research on the assessment and presentation of AD in 
the DS population (see Prasher, 2005). The neuropsychological assessment of 
AD in the DS population in particular, poses great challenges in comparison 
to its assessment in the general adult population (see Section 1.13 for review 
of these difficulties). These difficulties often mean that longitudinal 
administrations of assessment are generally required. Additionally, other 
conditions have been identified which mimic the symptoms of AD, for 
example, depression, thyroid dysfunction, and vision and hearing problems 
(e.g. Oliver, Crayton, Holland, & Hall, 2000; Prasher, 1999; Walker, Dosen, 
Buitelaar, & Janzing, 2011). These and other possible causes of symptoms 
must be fully considered in order to accurately assess and clinically diagnose 
AD in this population.  
 
In the general adult population, there is a reasonable understanding of the 
hypothesised cognitive continuum of ‘normal’ ageing, mild-cognitive 
impairment (MCI) and ‘pathological’ ageing, such as AD (Portet et al., 2006). 
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This increased knowledge has improved the clinical diagnosis of the latter 
two conditions. Research is only just beginning to examine this continuum in 
the DS population. For example, a research project is currently underway to 
examine whether the clinical concept of MCI can be diagnosed in this 
population (Krinsky-McHale, 2013) which may or may not lead to AD. In the 
past 20 years, research has also begun to investigate the changes in cognitive 
functioning which occurs in the ‘normal’ ageing process in people with DS 
(see Zigman et al., 2008). ‘Normal’ ageing is characterised by a decline in 
memory and other cognitive abilities which are typically expected as people 
age. For instance, episodic, prospective and working memory begin to show 
slight changes around twenty years of age with further decline over time in 
the general adult population (e.g. Brickman et al., 2009; Nilsson, 2003).  
 
Distinguishing between AD and ‘normal’ ageing is important for assessment, 
clinical diagnosis and intervention purposes. In the general population, 
‘normal’ ageing provides the baseline from which a clinical diagnosis of MCI 
or AD is made (Grundman et al., 2004). It is important therefore to 
understand what ‘normal’ ageing represents in the DS population. This 
would allow clinicians to establish whether any clinically observed 
deterioration in cognitive functioning is indicative of ‘normal’ ageing or AD 
as well as improving the likelihood of early diagnosis. This systematic 
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review will review the research on memory changes associated with ‘normal’ 
ageing. Prior to this, the literature relevant to this systematic review will be 
outlined.  
 
1.1.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common form of dementia which is 
characterised by a progressive loss of memory, deterioration in at least one 
other cognitive function (e.g. executive function) and reduced capacity for 
tasks of everyday living (American Psychiatric Association, 1994). In 2010, 
there was an estimated 35.6 million people with dementia worldwide. This is 
expected to increase exponentially to an estimated 65.7 million by 2030 and 
to 115.4 million by 2050 (Prince et al., 2013). The mortality rates vary across 
studies but research has reported that following a diagnosis at age 60-70 the 
median mortality rate is approximately 6-10 years, by age 70-80 this reduces 
to 3 years and in the 90s to 2 years (Brookmeyer, Corrada & Curriero, 2002; 
Rait et al., 2010). Death typically results from other health issues such as 
circulatory and more commonly, respiratory system diseases (e.g. 






1.1.2 Alzheimer’s disease in Down syndrome (DS) 
Down Syndrome (DS) is the most common genetic cause of intellectual 
disability, affecting about one in every 1000 live births in the UK (Down 
Syndrome Association, 2012; Sherman, Allen, Bean, & Freeman, 2007). 
Historically, people with DS did not survive past childhood. In 1929, the life 
expectancy of people with DS was nine years of age (Penrose, 1949). In recent 
years, with the advances in medical treatment and with 
deinstitutionalisation, increasing numbers of people with DS are reaching 60 
years of age and beyond (Bittles & Glasson, 2004; Torr, Strydom, Patti, & 
Jokinen, 2010).  
 
The association between DS and AD has been well documented (see Prasher, 
2005). Historically, it was believed that all people with DS eventually 
develop the condition, as DS is caused by a superfluous copy of chromosome 
21 which is implicated in development of AD (Webb & Murphy, 2012). 
Additionally, post-mortem studies showed that at the age of 40 years, the 
majority of people with DS exhibit the neuropathological indicators of AD 
(Mann, Yates, & Marcyniuk, 1984; Wisniewski, Wisniewski, & Wen, 1985). In 
particular, the widespread formation of neuritic plaques and neurofibrillary 
tangles in the brain. However, more recent studies have revealed that not all 
people with DS demonstrate the clinical characteristics of the disease (e.g. 
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Coppus et al., 2006; Krinsky-McHale, Devenny, Kittler, & Silverman, 2008). 
This implies that although there is an association between the 
neuropathology of AD and DS, as yet, the exact relationship between them is 
not completely known. It also suggests that AD is not inevitable in all adults 
with DS (Prasher, 2005). Prevalence rates of dementia are comparable to the 
general population, but occur 30-40 years earlier in people with DS (Holland, 
Hon, Huppert, & Watson, 1998).  
 
1.1.3 Neuropsychological assessment of Alzheimer’s disease in DS 
Neuropsychological assessment has a significant role to play in the 
assessment and diagnosis of AD (Scottish Intercollegiate Guidelines Network 
[SIGN], 2006; National Institute for Health and Clinical Excellence [NICE], 
2006). However, assessing for AD in people with DS is particularly 
challenging. The variability in their intelligence poses challenges in 
interpreting performance on single neuropsychological assessments (e.g. 
Crayton, Oliver, Holland, Bradbury, & Hall, 1998). Their performance may 
be within the cut-off points suggestive of cognitive deterioration associated 
with AD, however, their score may be a reflection of their pre-existing 
intellectual disability (ID) not a cognitive deterioration. For this reason, 
longitudinal administration of tests is recommended (Burt & Aylward, 2000). 
This however, is not without its difficulties. Standardised 
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neuropsychological assessments that have been adapted from the normal 
adult population often result in ‘floor’ effects (Crayton et al., 1998). This 
means that people often score zero or obtain the lowest scores on the test due 
to their ID. As a consequence, the tests are unable to determine a 
deterioration in function (e.g. Stanton & Coetzee, 2004). As a result of these 
challenges, it was believed that testing people with pre-existing cognitive 
impairments concealed the diagnosis of AD dementia in people with DS (see 
reviews by Nieuwenhuis-Mark, 2009; Zigman & Lott, 2007). Despite these 
difficulties with assessments there has been an abundance of research 
examining the cognitive changes associated with AD in people with DS (e.g. 
Devenny, Krinsky-McHale, Sersen, & Silverman, 2000; Margallo-Lana et al., 
2007; Oliver et al., 1998). However, with time assessments have been 
adapted, developed and improved (Silverman et al., 2004) taking into 
account the above difficulties. 
 
1.1.4 Cognitive decline in the general population with ‘normal’ ageing 
In the general population, there is a gradual decline in memory as people age 
‘normally’ with different memory systems exhibiting differential 
susceptibility to ageing (reviewed by Brickman & Stern, 2009). Broadly, the 
most stable memory systems across the life span appear to be: perceptual, 
procedural (i.e. practiced habit procedures), and semantic (i.e. general 
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knowledge about the world) (e.g. Craik, 1998; Nilsson, 2003). Systems that 
show decline are episodic (i.e. specific events) and working memory (i.e. 
information held and manipulated) (e.g. Luo & Craik, 2008; Nyberg, 
Backman, Erngrund, Olofsson, & Nilsson, 1996). From around the age of 20 
years of age there is an almost linear age-related decline in episodic and 
working memory (see Salthouse, 2010 for review).  
 
Performance on episodic tasks that show changes with ‘normal’ ageing are 
those that involve free recall of information (i.e. when people have been 
given no cues to help them to retrieve information) (e.g. La Voie & Light, 
1994) and tasks that ask people to retrieve the context or source of an event 
(e.g. Cansino, 2009; Spencer & Raz, 1995). Tasks of prospective memory 
which involves asking people to carry out a future act without a prompt (e.g. 
Henry, McLeod, Phillips, & Crawford, 2004) also demonstrate decline. 
Additionally, performance that requires people to change information in 
their mind without help, namely working memory tasks, show declines with 
‘normal’ ageing (Craik & Jennings, 1992). Evidence has shown that working 
memory mediates decline in other memory systems and cognitive functions 




There is variability in memory performance in the trajectory of ‘normal’ 
ageing. As a result, researchers have examined the risk factors that may 
influence memory, such as cardiovascular risk factors and ‘cognitive reserve’ 
(see Brickman & Stern, 2009).  
 
It is important to note that studies which have examined ageing may have 
included participants with dementia which may confound the ‘normal’ 
ageing evidence base (Crayton et al., 1998). Additionally, changes in 
performance, particularly in episodic memory, have employed cross-
sectional designs which may overestimate the changes over time (Nilsson, 
2003).  
 
Standardised norms for different neuropsychological tests provide the most 
valuable information on age trends in cognitive functioning (see Salthouse, 
2010). Additionally, standardised norms of different tests acknowledge that 
various cognitive functions are influenced by age. For example, the 
Rivermead Behavioural Memory Test, 3rd edition (RBMT3, Wilson et al., 
2008), examines verbal, visual, spatial, prospective memory and new 
learning. This test demonstrates that a raw score of 10 on the immediate 
recall of a story (i.e. free recall) will have a scaled score of: 10 for people aged 
16-24 years; 11 for people aged 45-54 years; and 13 for people aged 75-89 
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years. Therefore, as people age, free recall of verbal information decreases. 
Tests also provide ‘normal’ ageing norms and provide cut-offs for 
‘pathological’ ageing (e.g. ACE-R, Mioshi et al., 2006). Hence, these norms set 
the baseline from which ‘pathological ageing’ is identified.  
 
1.1.5 Rationale for the current review 
Given the evidence that the general adult population show memory changes 
associated with ‘normal’ ageing and the known difficulties with 
differentiating between AD, pre-clinical AD and ‘normal’ ageing in DS (Ball 
et al., 2006), it is important to review what we know of ‘normal’ ageing in the 
DS population. A clearer understanding of this area should aid clinicians 
with their diagnosis of memory (and other cognitive) difficulties, and also 













This review will address the following question with the aim of advancing 
our knowledge and understanding of potential changes in memory 
associated with ‘normal’ ageing in adults with DS. This review will consider:  
 
Question:  Are there memory changes associated with ‘normal’ ageing in 
adults with DS? What types of memory show changes and at 

















1.3.1 Inclusion and exclusion criteria  
The framework PCOS (population; comparators; outcomes; study design) 
described by the Centre for Reviews and Dissemination guidelines (CRD, 
2008) was used to guide the selection of studies for inclusion and exclusion in 
this review. This is an internationally recognised framework commonly used 
in systematic reviews (Needleman, 2003). Only articles available in the 
English language were included. 
 
1.3.2 Population  
Studies were included in the review if their main aim was to assess cognitive 
changes associated with ‘normal’ ageing and if at least half of the 
participants included adults (aged over 18) with a diagnosis of Down 
syndrome (DS). Studies were excluded if their primary focus was on 
examining the cognitive changes associated with dementia. That is, studies 
that included participants with a diagnosis of dementia were excluded. 







Memory was the area of interest explored in the review. Studies with a 
comparison or control group of participants with intellectual disabilities (ID) 
(other than DS) were included.  
 
1.3.4 Outcome measures  
Memory was the main outcome measure. Only studies which used 
standardised neuropsychological assessments to assess memory were 
included in the study.  
 
1.3.5 Study design  
The Scottish Intercollegiate Guidelines Network (SIGN, 2012) was used to 
assess the quality of studies. SIGN is recognised as one of the most robust 
scoring systems for assessing the quality of evidence (Schünemann, 
Fretheim, & Oxman, 2006). It is an original member of the Guidelines 
International Network and aims to meet the standards of the AGREE 
(Appraisal of Guidelines, Research and Evaluation) Instrument. This is an 
internationally recognised review system (SIGN, 2012).  
 
Case-series and case reports studies were excluded due to the risk of bias in 
these articles. Additionally studies with no objective data, in particular, 
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literature reviews, systematic reviews, unpublished dissertations and book 
reviews, were also excluded.   
 
1.3.6 Search strategy and identification of relevant literature 
In order to ensure that the review had not already been completed 
previously the following were searched: The Cochrane Library database of 
Cochrane Database of Systematic Reviews (Cochrane Reviews); Cochrane 
Central Register of Controlled Trials (Trials); National Institute of Health and 
Clinical Excellence (NICE); and the SIGN guidelines (see Appendix 2, Table 
1). No reviews were found which addressed the aim of this review.  
 
Following this a wide range of databases were searched to identify relevant 
literature (see Appendix 2, Table 1). In order to provide a comprehensive 
review, databases were searched from the year they began till July 2012. 
These included: the OVID databases: EMBASE (1974 - July 2012) and 
MEDLINE(R) (1946 - July 2012); EBSCO databases: PsycINFO (1987 – July 
2012); CINAHL (1981 – July 2012); and Applied Social Sciences Index and 
Abstract (ASSIA) (1987-July 2012). Reference lists from relevant studies of 
frequently cited articles were examined further to ensure that all studies had 
been identified. This was completed using the Web of Science database and 
the general search engine Google and Google Scholar (Appendix 2, Table 2). 
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A combination of free text key word searches and subject headings were 
used to identify relevant articles. The main search terms were ageing, 
neuropsychological tests and Down syndrome. A variety of search terms 
were used for each of these terms and then combined with OR (Appendix 2, 
Table 1). The titles and abstracts of studies were read to ascertain whether 
the whole article was relevant to be included in the review prior to excluding 
studies. Whole articles were retrieved if this was unclear.  
 
1.3.7 Quality assessment of included studies  
The methodological quality of the included studies were examined by 
adapting the “Methodology Checklist 3: Cohort Studies” (SIGN, 2001-2012). 
As the focus of this review is concerned with changes associated with ageing, 
longitudinal studies were considered to be more robust (Christensen, 2001) 
and therefore studies included were separated by design and then ranked by 
quality criteria. Quality criteria are described below in Table 3 (see Appendix 
3) with the maximum total score awarded being 28 points. 
 
Each article was assessed by the first author and an independent reviewer. If 
consensus was not achieved, this was discussed and the study in question 





In total, 216 articles were identified by the systematic search of the literature. 
The titles were screened initially to eliminate irrelevant articles (N=41). These 
were articles that examined aging in relation to physical health, such as 
menopause or gait development or in terms of neuro-anatomy, rather than in 
relation to cognitive functioning. 175 articles remained. Of these, the titles 
and abstracts were then examined and articles were excluded that did not 
meet the primary inclusion criteria. These were articles which examined: 
changes in cognitive functioning associated with dementia; neuroanatomy; 
the effectiveness of medication; review articles; articles which examined the 
effects of dementia on caregivers; epidemiology; neuropsychology in relation 
to dementia and diagnosing Alzheimer’s disease. If it was unclear whether 
an article met the inclusion or exclusion criteria on the basis of the title and 
abstract, it was examined as a full text article. As a result, 65 articles 
remained. The full texts of these potentially relevant citations were retrieved 
and all PCOS criteria were then used systematically to assess for eligibility. 
Eight articles met the criteria for inclusion in the current review. Further 






Figure 1. Process of excluding articles for current review. 
Titles retrieved from searches were read (n=216) 
Studies excluded that were 
unrelated to current review 
 Excluded (n=41) 
Included studies for review  
(n=8)  
Duplicates articles 
 Excluded (n=17) 
 
Full articles retrieved for further 
evaluation (n=65) 
 
Studies excluded if: 
 
 Population:  
Aim was to examine cognitive 
changes associated with 
dementia (n=17) 
Validating a 
neuropsychological test (n=2) 
Participants <18 years of age 
(n=2) 
Participant sample other than 
DS as main sample (n=1) 
 
 Comparator:  








 Study Design 
Review /unpublished 
dissertation / book (n=3) 
Case Study (n=4) 
 
Primary Criteria (population): 
Articles which did not examine 




Titles and abstracts of potentially 
relevant articles read (n=175). 
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Table 4 summarises: (a) design; (b) participant numbers; (c) IQ assessment; 
(d) neuropsychological measures used; (e) memory changes; (f) reported 
effect size; and (g) quality ratings awarded to each included article. The table 
is ordered in terms of the quality rating of each article with better quality 
studies at the top of each section. The first part of the table displays 
longitudinal designs and the second half displays cross-sectional.  
 
Quality ratings were not categorised into an overall category rating (i.e. good 
or poor) as it was thought that this would be highly subjective. Longitudinal 
studies scored lower in terms of their quality (8-13 points) to cross-sectional 
studies (13-20 points). Nevertheless, as mentioned previously longitudinal 
studies were considered more robust for this type of review. Therefore, they 
were given more weight in terms of their findings than the cross-sectional 
studies and will be considered separately. For a detailed itemisation and 
summary of each individual quality rating (not including design), see, Table 
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Yes No significant age 
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PM BNT; VeMT; 
PM; Copy of 
Drawings  
 
No Young DS lower mean 
scores in verbal 
memory than Mixed 
ID (not sig.)  
Sig. Difference 
between Old DS and 
AD group in verbal 
memory test.  
No noted differences 





Abbreviations: AD: Alzheimer’s disease; BPVS: British Picture Vocabulary Test; BMT: Buschke Memory Test; BNT: Boston Naming Test; 
CAS: Cognitive Assessment (Das-Naglieri); DS: Down syndrome; DRS: Dementia Rating Scale; EMS: Evaluation of Mental Status; IBR: 
Evaluation of Mental Status; ID: Intellectual disabilities; MAT: Matrix Analogies Test; PM: Progressive Matrices; OCDB: Oliver and Crayton 
Dementia Battery; PM: Program Matrices; PPVT-R: Peabody Picture Vocabulary Test, Revised; Picture Fragment Completion Task; RBMT-
C: Rivermead Behavioural Memory Test-Children’s Version; SRT: Selective Reminding Test; SBR: Standford-Binet Ration IQ; VeMT: Verbal 





1.4.1 General characteristics of included studies 
Two studies were carried out in the UK (Carr, 2003, 2012), one in Italy 
(Caltagirone, Nocentini, & Vicari, 1990), three in America (Devenny, Hill, 
Patxot, & Wisniewski, 1992; Devenny et al., 1996; Krinsky-McHale et al., 
2003; Devenny, Zimmeril, Kittler, & Silverman, 2002) and two in Canada 
(Das & Mishra, 1995b; Das, Divis, Alexander, Parrila, & Naglierii, 1995a). 
Four articles employed a longitudinal design to examine a total of 171 
participants with DS (Carr, 2003, 2012; Devenny et al., 1992, 1996). Four 
articles employed a cross-sectional design to examine a total of 108 
participants with DS (Caltagirone et al., 1990; Das et al., 1995a; 1995b; 
Krinsky-McHale et al., 2003). The observation periods for the longitudinal 
designs ranged from 3 years (Devenny et al., 1992) to 15 years (Carr, 2012).  
 
1.4.2 Participant characteristics 
The size of the sample of people with DS ranged from 11 (Das et al., 1995b) to 
91 (Devenny et al., 1996). Their ages ranged from 30 years (Carr, 2003, 2012) 
to 69 years (Das et al., 1995b). Two articles did not report the age range of 
their sample and reported the means instead (Caltagirone, 1990; Krinsky-




Recruitment of participants in studies involved purposive sampling from 
day centres (Caltagirone et al., 1990), public services (Das et al., 1995a) and 
the community (Carr, 2003, 2012; Das et al., 1995b; Devenny et al., 1992, 1996; 
Krinsky-McHale et al., 2003).  
 
Sampling criteria in the form of inclusion and exclusion criteria were 
reported for six of the studies for the participants and comparison groups 
(Caltagirone et al., 1990; Carr, 2003, 2012; Devenny et al., 1992, 1996; Krinsky-
McHale et al., 2003). The inclusion criteria were mainly: no history of 
seizures, no evidence of a dementing process, no severe sensory or motor 
impairment (Caltigirone et al., 1990; Devenny et al., 1992; 1996); and IQ over 
35 (Devenny et al., 1992, 1996). Devenny et al. (1992) specified that 
participants had to be over 25 years of age and Devenny et al. (1996) 
included participants 30 years of age and over. Carr (2003, 2012) accepted all 
babies with DS born during one year in one geographical area and did not 
report any other criteria for inclusion. They used this as their sample to 
follow longitudinally but only examined memory functioning from the age 
of 30 years. Two studies did not report inclusion or exclusion criteria (Das et 





1.4.3 Assessment of IQ 
Three studies did not assess for intelligence in their sample (Devenny et al., 
1992, 1996; Krinsky-McHale et al., 2003). Instead IQ was obtained from 
examining the clinical records of their participants and recording the results 
of their most recent assessment. The type of assessment employed to 
calculate the Full Scale IQ was not documented in the published research 
studies.  
 
Four articles assessed for IQ in their study. A range of tests were used 
including: British Picture Vocabulary Scale (BPVS; Dunn et al., 1982) and the 
Leiter International Performance Scale (Leiter, 1980) (Carr 2003, 2012); 
Peabody Picture Vocabulary Test-Revised (PPVT; Dun and Dun, 1981) (Das 
et al., 1995b); and Progressive Matrices’47 (Raven, 1949) (Caltigirone et al., 
1990). The final study (Das et al., 1995a) reported the use of assessments 
available in clinical files (i.e. Wechsler Adult Intelligence Scale or Standford 
Binet ratio IQ) but also carried out further assessment as part of their study 
namely the PPVT-R and Matrix Analogies Test-Expanded Form (MAT; 
Naglieri, 1985).  
 
Participants varied in their Full Scale IQ. One article reported the range of IQ 
in their sample (41-77 in <35 year group and 45-64 in >35 year group) 
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(Devenny et al., 1992). Most articles reported the mean IQ (Carr, 2003, 2012; 
Das et al., 1995a, 1995b; Devenny et al., 1992, 1996; Krinsky-McHale et al., 
2003) which ranged from 41.3 to 55.8 across studies. Caltagirone et al. (1990) 
did not report on the IQ level in their sample.  
 
In summary, a variety of measures were used to assess for IQ in the included 
studies which created difficulties when attempting to generalise the data. 
Additionally, a few studies took IQ scores from clinical files but failed to 
report on the measure used. This also creates difficulty when comparing 
findings.  
 
1.4.4 Comparison groups  
Six articles included a comparison group of participants with intellectual 
disabilities of different aetiologies (Caltigirone et al., 1990; Das et al., 1995a, 
1995b; Devenny et al., 1992, 1996; Krinsky-McHale et al., 2003). Caltigirone et 
al. (1990) also included a group of participants with intellectual disabilities of 
different aetiologies who were, on the basis of neuropsychological tests, 
considered to be suffering from Alzheimer’s disease. Two articles did not 
include a comparison group (Carr, 2003, 2012), however, the authors had 




Of the six studies that used comparison groups, five reported on the age of 
their sample. For three of the studies (Das et al., 1995a; Devenny et al., 1992; 
Krinsky-McHale et al., 2003), the DS groups were found to be younger than 
the ID group. Das et al. (1995a) reported that the young DS group was 3.69 
years younger than the young ID group, and the old DS group was 2.13 years 
younger than the old ID group. Devenny et al. (1992) reported that the young 
DS group was 0.7 years younger than the young ID group and the old DS 
group were 2.3 years younger than the old ID group. Krinsky-McHale et al. 
(2003) reported that the mean age of their DS group was 10 years younger 
than the ID group. For one of the studies (Caltagirone et al., 1990) the DS 
group was found to be older than the ID group by 9.3 years. Devenny et al. 
(1996) reported that with their 30-39 year group, the DS group were older by 
one year; in the 40-49 age group, they were matched for age and in the over 
50 group the ID group were 6 years older than the DS group. Das et al. 
(1995b) did not report the mean or median of their sample so the 
appropriateness of their matching could not be reported. 
 
In terms of IQ, the six studies which had comparison groups varied in their 
matching of groups (Caltagirone et al., 1990; Das et al., 1995a, 1995b; 
Devenny et al., 1992, 1996; Krinsky-McHale et al., 2003). Four studies 
reported IQ ranges, with mean IQ scores ranging from 51.46-59.07 (Krinsky-
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McHale et al., 2003; Das et al., 1995a; Devenny et al., 1992, 1996). One study 
(Das et al., 1995b) reported on mean mental age determined by PPVT-R 
scores. There was a difference of one year and nine months between their DS 
and ID comparison samples. However, the difference was not significant 
according to the authors. Nevertheless, Das et al. (1995a) found lower mean 
IQ scores for the DS groups than their corresponding ID groups (differences 
of 8.56 IQ points and 1.65 IQ points for the young adult and old adult 
groups). The authors reported that the matching was not ‘completely 
satisfactory’.  
  
Four studies did not assess for IQ in their samples but gathered information 
from clinical files (Caltagirone et al., 1990; Devenny et al., 1992; 1996; 
Krinsky-McHale et al., 2003). The assessment used was not reported, 
therefore, it is difficult to ascertain whether the groups were well matched. 
There was a mean difference of 7.61 IQ points difference between the ID and 
DS group (with ID groups being higher) in Krinsky-McHale et al.’s study 
(2003). Devenny et al. (1992) found a difference of 3.9 IQ points difference 
between DS and ID in the under 35 age group, and a difference of 0.5 IQ 
points in the over 35 age group. Devenny et al. (1996) reported differences of 
13 IQ points in the 30-39 age group, five IQ points in the 40-49 age group and 
seven IQ points in the over 50s age group. All of the differences were in the 
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direction of higher scores in ID groups than DS groups. Caltagirone et al. 
(1990) did not report on the IQ level in their comparison samples.  
 
1.4.5 What types of memory have been examined?   
Four studies assessed episodic memory (Caltagirone et al., 1990; Devenny et 
al., 1992, 1996; Krinsky-McHale et al., 2003), typically tests of verbal memory 
(Caltagirone et al., 1990; Devenny et al., 1992, 1996). Tests of visual memory 
were also included in two studies (Devenny et al., 1992, 1996). One study 
examined implicit memory (Krinsky-McHale et al., 2003).  
 
Four studies used batteries of neuropsychological assessments, which 
included tests of memory (Carr, 2003, 2012; Das et al., 1995a, 1995b). Batteries 
of assessments such as the Rivermead Behavioural Memory Test-Children’s 
Version (RBMT) and Oliver and Crayton Dementia Battery (OCDB) were 
used in two studies (Carr, 2003, 2012). Within these batteries different aspects 
of memory were assessed for using the following subtests such as: name 
learning, remembering, picture memory, story recall, faces, route, message 
and memory for sentences. Two studies used the Das-Naglieri Cognitive 
assessment system (Das et al., 1995a, 1995b). This battery includes tests of 




1.4.6 Have other cognitive functions been examined? 
Three studies examined changes in IQ with age (Carr, 2003, 2012; Das et al., 
1995a). The longitudinal data showed small but insignificant declines in IQ 
were evident with ageing from 30 to 35 years (Carr, 2003). However, in their 
longitudinal study, Carr (2012) found that IQ remains relatively stable until 
the age of 45 years. However, Carr (2012) only assessed participants up until 
the age of 45 years. Whilst, Das et al. (1995a) in a cross-sectional study found 
that IQ showed signs of decline after the age of 50 years.  
 
Three studies (Das et al., 1995a, 1995b; Devenny et al., 1996) also examined 
other cognitive functions. Two studies reported differences between older 
people with DS and younger people with DS on tests of planning and 
attention (Das et al., 1995a, 1995b) such that people over the age of 40 
perform poorer than those under the age of 40 years. One study of 
longitudinal design considered that older people are poorer at tasks 
involving speed of motor processing (Devenny et al., 1996), suggesting 
processing speed declines with age in people with DS. Although there are 
some differences noted with age in terms of cognitive abilities other than 
memory, there is not enough evidence to make conclusions as only three 




1.4.7 Screening and assessing for dementia 
Three studies (Devenny et al., 1992, 1996; Krinsky-McHale et al., 2003) made 
some effort to screen for dementia prior to enrolment to the studies. A 
variety of methods were used, including screening for a history of functional 
loss in the clinical notes and by way of informal discussion with care workers 
(Devenny et al., 1992, 1996). One study did not screen but specified the 
exclusion of participants with a diagnosis of dementia or that exhibited 
significant declines on the memory measures employed in their study 
(Krinsky-McHale et al., 2003). Three studies did not attempt to screen or 
exclude participants for dementia (Caltagirone et al., 1990; Das et al., 1995a, 
1995b). Screening for dementia prior to enrolement in the research was not 
relevant for Carr (2003, 2012) as they recruited at 6 weeks of age.  
 
Dementia was also screened for during the research process. Of the eight 
studies, four studies included an assessment to help to distinguish ‘normal’ 
ageing from ‘pathological’ ageing, specifically dementia (Carr, 2003, 2012; 
Das et al., 1995a; Devenny et al., 1996). Carr (2012) confirmed or suspected 
dementia for eight participants in their study. These participants showed 
significant declines on the RBMT-C (20-39 points) and showed large declines 
on the OCDB (16-25 points). The authors did not report how the diagnosis 
was made, for example diagnostic criteria or multidisciplinary assessment. In 
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comparison, Devenny et al.’s (1996) study described the assessment of 
dementia including multidisciplinary assessment, diagnostic criteria (i.e. 
DSM-III-R) and discussion with regard to conditions that may have 
mimicked the symptoms. They found that four of their 91 participants 
showed changes associated with AD. They also reported that the four 
participants demonstrated personality changes, a progressive decline in 
cognitive performance and these affected their daily living skills. Das et al.’s 
(1995a) study used the Dementia Rating Scale (DRS) which demonstrated 
significant decline in the older DS group. The authors discussed this as 
‘ageing’ but it was unclear whether the change was due to AD rather than 
‘normal’ ageing. They also reported that careful medical screening should be 
carried out in future research but did not report on their employment of this 
in their study.  
 
In those suspected of dementia, seven of the studies did not assess or screen 
for conditions which may have produced cognitive impairment, such as 
depression or thyroid dysfunction. Only Devenny et al.’s (1996) study, 
assessed for depression, anxiety and thyroid dysfunction in the individuals 




1.4.8 Systematic review question: Are there memory changes associated 
with ‘normal’ ageing in adults with DS? What types of memory show 
changes and at what age do these occur? 
 
Based on the results from the four longitudinal studies (Carr, 2003, 2012; 
Devenny et al., 1992, 1996), there appears to be some changes in memory as 
adults with DS increase in years (Carr, 2003, 2012; Devenny et al., 1996). 
However, these changes were not statistically significant.  
 
A small deterioration has been noted as early as 35 years in people with DS 
in terms of verbal and visual recall and in immediate and delayed memory 
tasks (i.e. episodic memory) and memory for remembering a route (i.e. 
spatial memory) (Carr, 2003). These slight deteriorations continue up to 45 
years of age (Carr, 2012) with subtle changes in prospective memory noted. 
As this study only included participants up to the age of 45 years, changes 
beyond these were not studied. However, Devenny et al. (1996) found that 
older participants over 50 years of age with DS show poorer performance on 
episodic memory tasks of free recall compared with younger people with DS 




Devenny et al.’s (1992) longitudinal study found no age-associated changes 
in visual memory and no deterioration in test scores over a 3-5 year period. 
Although this study included participants with DS up to 55 years of age, 
given this short time period of assessment, it is unlikely that the authors 
would have found changes. However, Devenny et al.’s (1996)’s study over a 
six year period, confirmed these finding by reporting no evidence of decline 
in short-term visual memory ability in adults up to the age of 63 years of age.  
 
The cross-sectional studies reported no age-associated changes in verbal, 
implicit memory or visual memory (Das et al., 1995a, 1995b; Caltagirone et 
al., 1990; Krinsky-McHale et al., 2003). Das et al. (1995a; 1995b) studies 
examined participants from 26-62 years age range. The other two studies did 
not report on the age range in their studies but reported on the mean instead. 
In this case, the mean was 28 years for the younger group and 39.5 years for 
the older group (Caltagirone et al., 1990) with an overall mean of 43.65 years 
(Krinsky-McHale et al., 2003). In terms of the comparison groups, one study 
was not well matched for IQ (Das et al., 1995a) one did not report the IQ level 
in their comparison sample (Caltagirone et al., 1990) and one had higher IQ 
in the ID group, but this was not significant (Krinsky-McHale et al., 2003). 
Hence, this may have influenced the results. While appropriate tests were 
employed, the authors only tested one type of memory. For example, only 
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implicit (Krinsky-McHale et al., 2003) verbal (Caltagirone et al., 1990) and 
visual (Das et al., 1995a, 1995b) memory were examined. Additionally, the 
sample sizes within the studies were relatively small (ranging from 11-48 
participants), therefore, it is unlikely that any differences in memory ability 
would have been demonstrated.   
 
Overall, one longitudinal study and four cross-sectional studies did not 
report any memory changes associated with ageing, however, due to their 
limitations it is difficult to draw conclusions. As previously discussed, 
longitudinal research is more suited to ageing research, therefore those 
studies were deemed more robust.  
 
Based on these results only, there appear to be some evidence for subtle 
changes in memory associated with ‘normal’ ageing in people with DS. There 
were slight episodic memory and spatial memory changes which began 
around age 35 years of age then changes in prospective memory from 45 









1.5.1 Summary of the evidence 
The research literature examining memory changes associated with ‘normal’ 
ageing is sparse in comparison to the literature base examining Alzheimer’s 
disease (AD) in the Down syndrome (DS) population (see Lott, 1982; 
Zigman, Silverman, & Wisniewski, 1996, for reviews). Of the studies 
included in this review, three studies noted subtle changes in episodic, 
spatial and prospective memory associated with ‘normal’ ageing (Carr, 2003, 
2012; Devenny et al., 1996) whilst the other five studies did not. The three 
studies that did show changes were considered more robust due to their 
longitudinal design. Therefore, from the literature, it appears that there may 
be subtle changes in episodic, spatial and prospective memory which are 
consistent with the cognitive changes associated with ageing in the general 
adult population (see Kausler, 1994; Newman & Kasniak, 2000). However, 
given the limited range of memory abilities tested it is unclear whether there 
are changes in other types of memory as people with DS age ‘normally’. 
Evidence from the general population has suggested that there are also 




In terms of determining at what age people demonstrate memory changes, it 
is not clear given the lack of studies available for review and of those that 
were reviewed five did not demonstrate any changes in memory. Of the 
studies that demonstrated changes, two followed their samples from 30-45 
years of age and noted subtle changes age in episodic, spatial and 
prospective memory at 35 years of age which continued up until 45 years of 
age (Carr, 2003, 2012). The third study demonstrated that people with DS 
over 50 years of age showed poorer performance on episodic memory tasks 
of free recall compared with younger people with DS (Devenny et al., 1996). 
Four of the five studies that did not find any changes may have been due to 
their cross-sectional design and limited samples which may have reduced 
their ability to demonstrate any differences between groups. Furthermore, 
only one study reported an effect size, however, this may have been due to 
the restricted samples available. 
 
Overall, this review has not been able to fully establish whether there are 
memory changes, which memory abilities change and when these changes 
take place with ‘normal’ ageing in people with DS. Furthermore, there are 





1.5.2 Methodological limitations 
There are significant methodological limitations apparent in the reviewed 
studies. Of the limited studies available for review, there has been difficulty 
synthesising the data due to the inherent differences in the: type of 
neuropsychological tests employed; age range of samples; IQ range; and 
sample size of participants. This heterogeneity has reduced the review’s 
ability to make meaningful comparisons. 
 
The majority of studies did not employ neuropsychological tests with robust 
psychometric properties. As mentioned previously, there is a lack of memory 
tests available for use with people with DS (Crayton et al., 1998). 
Additionally, the psychometric properties of memory tests have yet to be 
established as there is a lack of normative data available for the DS 
population.  
 
There was limited assessment of other cognitive functions in the reviewed 
studies. Memory abilities cannot be clearly understood without 
comprehensive assessment of other abilities. For example, it has been shown 
that executive functioning can impact on memory performance (Salthouse, 
Atkinson & Berish, 2003). Of the studies that examined other cognitive 
functions, an adequate range of assessments were not conducted.   
43 
 
None of the studies explicitly stated how they differentiated between 
cognitive changes associated with ‘normal’ ageing and ‘pathological’ ageing. 
Only one study reported clearly on their assessment and diagnosis of AD (i.e. 
employing the DSM-III-R guidelines). However, Aylward et al. (1997) 
working group suggested that the ICD-10 framework should be used to 
diagnose dementia in people with DS as it also emphasises non-cognitive 
changes associated with the disease. None of the other studies reported using 
classification systems to diagnose AD. Research has shown that the type of 
classification system used to diagnose dementia will significantly affect the 
prevalence rates of AD in research and clinical populations (Burt et al., 1998). 
Hence, it is difficult to ascertain whether the memory changes noted are in 
fact a ‘normal’ ageing process rather than early-onset AD.  
 
1.5.3 Implications for future research and clinical practice 
 
1.5.3.1 Research examining memory  
Research should firstly examine memory in the DS population. This review 
has shown that the changes in memory functioning in DS cannot be fully 
examined as there is little known about ‘normal’ memory functioning in this 
population. This research would also enable a more robust examination of 
what tests can assess memory and other types of cognitive functioning. 
44 
 
In order to fully understand and develop our knowledge base of memory 
functioning in DS it is essential to complete further research. This should 
focus on developing and adapting neuropsychological tests for use with 
people with DS. Additionally, substantial large scale research studies should 
be conducted to enable standardised data in which performance on memory 
assessments is stratified by age and intellectual abilities (i.e. IQ). In the 
general population, this information provides the most robust information 
about cognitive performance (see Salthouse, 2010). Only once there is a 
clearer understanding of memory functioning as people with DS age 
‘normally’, will clinicians be able to differentiate between ‘normal’ and 
‘pathological’ ageing.  
 
1.5.3.2 Research assessing ‘normal’ ageing changes in DS 
Due to the difficulties assessing for AD as outlined in the introduction, it is 
essential that the research examining ‘normal’ ageing is comprehensive and 
sufficiently thorough to assess for the possibility of AD in their participants 
so not to confound the ‘normal’ ageing literature.  
 
Longitudinal designs are most suited to research into ageing and can offer 
stronger inferences from their results in terms of the rates of decline amongst 
individuals (Hofer & Sliwinski, 2001). Additionally, they can make stronger 
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assertions regarding the association between different variables than cross-
sectional designs (Christensen, 2001). Larger samples are needed which 
should be monitored over a substantial period of time in order to observe 
any subtle changes. Multi-centre studies would be more beneficial as this 
would allow for larger groups of people with DS to be recruited as well as 
being able to explore the use of different types of neuropsychological tests. 
This research would help to identify methods for differentiating between 
‘normal’ ageing and AD. This, in turn, would also help clinicians to detect 
AD in this population and allow the implementation of early interventions 
for specific cognitive impairments and AD.    
 
Therefore, future research examining ‘normal’ ageing needs to incorporate 












1. Exclude for AD by:   
a. Using diagnostic guidelines used for the assessment of those 
suspected of developing AD. The working group recommends 
the use of ICD-10 (Aylward et al., 1997).   
b. Including participants at approximately 30 years of age to 
reduce the risk of AD and to ensure a thorough and 
comprehensive baseline level of cognitive functioning and daily 
living abilities.  
 
During the study: 
2. A valid and reliable neuropsychological battery of tests should be 
used consistently. 
3. Regular screening assessments for the onset of AD  
a. Including direct and informant measures. 
b. Multidisciplinary assessment of suspected AD.  
c. Health checks to assess for conditions which may mimic AD 
symptomology. 
d. Assessment of daily living skills, personality and mental health.  
4. Assessment of different cognitive functions (including different types 
of memory abilities).  
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These criteria are essential in order to fully establish the trajectory of 
cognitive changes with ‘normal’ ageing in the DS population and to 
differentiate this from ‘pathological’ ageing. 
 
1.5.5 Conclusions 
The aim of this review was to increase our understanding of memory 
changes associated with ‘normal’ ageing in adults with DS. From the 
findings discussed, there is currently insufficient evidence to address this 
research question. The studies included in this review were confounded by 
significant methodological limitations and the inherent difficulties 
conducting research in this area has limited the data available for review.  
 
This review has highlighted the difficulty of assessing memory functioning 
in the DS population. It is apparent that more knowledge is needed about 
people with DS and their cognitive abilities. Further concurrence is needed 
on the types of memory functioning that require assessment, which 
neuropsychological tests can be used and to determine what factors mediate 
and moderate memory functioning in people with DS. Only with increasing 
our understanding of the ‘normal’ memory functioning in people with DS, 
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Chapter 2: Overview  
 
The systematic review titled “Memory changes associated with ‘normal’ 
ageing in adults with Down syndrome: A systematic review” (Part I: Chapter 
1) demonstrated that further research is needed to understand ‘normal’ 
ageing in adults with Down syndrome and intellectual disabilities. This is 
essential in order to understand how ‘normal’ ageing differs from 
‘pathological’ ageing as this will aid dementia diagnosis. In order to detect 
changes in cognitive functioning, valid and standardised neuropsychological 
assessments are needed which are applicable for people with Down 
syndrome and intellectual disabilities. Therefore, the following empirical 
research project titled ‘Convergent validity of the Visual Association Test 
(VAT) in adults with intellectual disabilities’ was conducted with the aim of 
exploring this aspect of construct validity in a sample of adults with 
intellectual disabilities. This is followed by an extended report of the 
methodology (Chapter 4). Chapter 4 will be written in accordance with the 
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ABSTRACT: EMPIRICAL STUDY 
Background: Neuropsychological tests of memory are believed to offer the 
greatest sensitivity at detecting people at risk of developing dementia. 
However, there is a paucity of validated, standardised and appropriate 
neuropsychological assessments of memory for adults with intellectual 
disabilities. This study examines the one aspect of construct validity (i.e. 
convergent validity) of an associative memory test (Visual Association Test; 
VAT) in adults with intellectual disabilities. 
    
Methods: 40 participants (18-45 years) were recruited from Community 
Learning Disability Teams. Participants completed the VAT and subtests of 
the modified Cambridge Cognitive Examination (CAMCOG-DS). IQ was 
assessed using the Wechsler Adult Intelligence Scale, fourth edition (WAIS-
IV). Correlational analysis of the test variables was carried out. Participants 
with a diagnosis of dementia were excluded from the study. 
 
Results: All participants performed well on the VAT irrespective of age, 
gender or IQ. It was well received by participants. No significant correlations 
were found between the VAT and the subtests of the CAMCOG-DS or with 
the subtests of the WAIS-IV. Therefore, there was no evidence of convergent 
validity with these tests in this sample of participants.   
 
Conclusions: While the VAT was found to be an easy and quick test to use 
with people with ID and all participants scored above ‘floor’ level, it was not 
found to have convergent validity with the CAMCOG-DS. Further research 
is needed to determine if the VAT represents a useful tool for assessment 
with this population.  
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Alzheimer’s disease (AD) is a progressive neurodegenerative disease which 
is the most common cause of dementia in the older adult population 
(Holtzman et al. 2011). AD is characterised by cognitive changes, in 
particular a deterioration in memory, as well as changes in the aptitude to 
perform everyday activities of daily life (Dickerson & Sperling 2008). A 
systematic review of the current evidence base for AD reported prevalence 
rates of 683,597 people suffering from AD in the UK with this being projected 
to increase by 38 per cent (940,110) by 2021 and by 154 per cent (1,735,087) by 
2051 (Knapp & Prince 2007).  
 
Dementia of the Alzheimer’s kind is also the most common cause of 
dementia in people with intellectual disabilities (ID) (e.g. Strydom et al. 
2007). People with ID have an increased risk of acquiring AD as they age, 
compared to the general population (British Psychological Society & Royal 
College of Psychiatrists 2009). People with Down syndrome (DS), in 
particular, have an increased risk of acquiring AD early in life (e.g. Tyrell et 
al. 2001) some 30-40 years earlier than the general adult population (e.g. 
Holland et al. 1998). With the rise in life expectancy, the incidence of AD is 
also predicted to increase in the future (Holland 2000). Therefore, AD will 
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place increasing demands on the NHS in the coming years, and research on 
early diagnosis has become a national priority (Department of Health 2009; 
Scottish Government 2010). 
  
Early diagnosis of AD is vital if pharmacological therapies are to be effective. 
Evidence has demonstrated that in the general population cholinesterase 
inhibitors are most effective when given at the earliest point prior to 
significant neuronal damage occurring (see Birks 2006 for a review). 
However, other non-pharmacological treatment approaches may also be 
beneficial. In a recent Cochrane review, Cognitive Stimulation Therapy (CST) 
(a psycho-social group-based intervention) was shown to be effective in 
improving the cognition of people with mild-moderate dementia in the 
general population (Woods et al. 2012). Regardless of the treatment approach 
used, early diagnosis allows for effective care planning for individuals and 
their families (National Institute for Health and Clinical Excellence NICE 
2006; Scottish Intercollegiate Guidelines Network SIGN 2006).  
 
Neuropsychological assessment is increasingly being recognised as having a 
crucial role, especially in the early identification of cognitive decline 
associated with AD (NICE 2006; SIGN 2006). Neuropsychological tests may 
be the most sensitive tools for identifying those at risk of developing the 
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disease (Lezak et al. 2004). There are a wide range of tests available for use in 
the general population (see Lezak et al. 2004). However, there is a paucity of 
neuropsychological assessments which are validated, standardised and 
appropriate for application with people with ID (Masson et al. 2010).  
 
One of the main obstacles for developing neuropsychological tools for the ID 
population is their pre-existing intellectual disabilities (Crayton et al. 1998). 
Neuropsychological assessments developed for use in the general population 
are often too complex and dependent on verbal abilities which can result in 
‘floor effects’ when applied to this population (Crayton et al. 1998). That is, 
the majority of people with ID score in the extremely low range or at zero on 
tests. This results in difficulties differentiating changes in cognitive ability 
associated with the onset of AD from difficulties in cognitive ability due to 
the ID. In addition, co-morbid health conditions, such as depression, 
epilepsy, and hyperthyroidism, are common in people with ID and can 
mimic the presence of AD or confound the test results (e.g. Burt et al. 1992; 
Das et al. 1995a; Devenny et al. 1996; Hanney et al. 2009).   
 
Accordingly, working groups have suggested that a standardised battery of 
tests should be employed longitudinally to assess dementia (Burt & Aylward 
2000). In other words, persons with ID are assessed prior to the typical age 
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when they are vulnerable to AD and periodically reassessed to monitor for 
any decline in functioning. Accordingly, in recent years, there has been an 
increasing interest in the neuropsychological functioning of people with ID, 
exploring what tests can be used and whether the tests can identify changes 
in functioning over time (see Prasher 2009 for a review). Neuropsychological 
assessments used in the adult population have been modified for use with 
people with ID, for example, the Cambridge Cognitive Examination 
(CAMCOG-DS; Ball et al. 2006) and the Test for Severe Impairment (Albert & 
Cohen 1992). Measures used in the child population have also been modified 
and validated for use with people with DS (RBMT-C; see Wilson & Ivani-
Chalian 1995). However, more research is needed on the adaptation of tests 
that have been shown to be sensitive to dementia in the general population.  
 
In the general population, episodic memory has been found to deteriorate in 
the initial stages of AD (Hodges 2000). Deteriorations in episodic memory are 
allied with atrophy in the medial temporal lobes (e.g. Braak & Braak 1991; 
Ewers et al. 2011). Additionally, the earliest neuropathological indicators of 
AD are the presence of neurofibrillary tangles and amyloid plaques in these 





Episodic memory is regarded as information which is received and stored 
about events and the relationships about these events (Tulving 1972). This 
type of memory is assessed by using recall and recognition tasks. For 
example, people are presented with visual or verbal information (e.g. objects 
or lists of words) asked to name them and then recall or recognise the 
information shown previously (Cabeza et al. 1997). In AD, both recall and 
recognition are affected over time (Hodges 2000). Free delayed recall is 
believed to be the measure which is sensitive to detecting the onset of AD 
(e.g. Thompson et al. 2011). However, poor performance on these tasks may 
be due to the difficulty placed on other cognitive functions or may be 
influenced by anxiety and depression (e.g. Kizilbash et al. 2002). People with 
specific conditions such as depression (e.g. Turner et al. 2012), Huntington’s 
disease (e.g. Montoya et al. 2006) and Parkinson’s disease (e.g. Elgh et al. 
2009), demonstrate more difficulties with free recall tasks. Recall is also more 
influenced by normal ageing in the general population than recognition (e.g. 
Parker et al. 2004).  
 
It is also imperative to assess recognition memory as deficits in this ability 
indicate that information has not been consolidated or stored properly, 
which is a hallmark of AD (Tierney 2001). Recognition tasks are not as 
demanding as recall tasks (Jarrold et al. 2007). Testing recognition can help to 
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differentiate between AD and other types of dementia (Graham et al. 2004). 
Furthermore, combining recall and recognition tasks can allow distinction 
between a retrieval or an encoding problem (Lezak 2004). Researchers argue 
that all memory tests should include a recognition trial to examine whether 
information has been encoded (Brown et al. 2010). This is especially 
important when free recall is impaired (Lezak 2004).    
 
Cued recall is also believed to be a more specific marker for diagnosing AD 
(Buschke et al. 1997; Fuchs et al. 2012). Cued recall provides a cue at the time 
of encoding to aid retrieval of the target information (Lezak 2004). 
Furthermore, adding a cue at the time of encoding the target, raises recall to 
the level of recognition (Lindeboom et al. 2002).  
 
The Visual Association Test (VAT) is a cued recall test that has been used in 
the general population (Lindeboom et al. 2002). It is a useful assessment for 
detecting early stage AD in the older adult population. It has also shown 
superiority and specificity over other tests of recognition (Fuchs et al. 2012). 
The VAT has also demonstrated the ability to discriminate AD from 
depressed and healthy individuals (Dierckx et al. 2007). Furthermore, studies 
have shown relationships with the VAT and hippocampal functioning (e.g. 
Henneman et al. 2009). 
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It has several attractive properties including that it is easy to administer, 
simple, quick to complete and ‘it is not confounded by age, education or 
depression’ (Lindeboom et al. 2002, pp. 132). It also does not rely heavily on 
language ability. Within the general population it has been shown to 
correlate with the Cambridge Cognitive Examination (CAMCOG) 
(Lindeboom et al. 2002) which is a neuropsychological test battery used in 
the general population that has been used to aid the assessment of dementia 
(e.g. Huppert et al. 1996). Specifically, the VAT corresponded with memory 
items (e.g. recognition) in the CAMCOG and thus, demonstrated convergent 
validity.   
 
The advantages of the VAT indicate that it may be a suitable tool for 
assessing memory in people with ID. There is also the potential for the VAT 
to screen for dementia in this population. However, before its usefulness as a 
screening tool for dementia can be examined, it is important to explore how 
people with ID perform on the test. If it can be shown that they can perform 
on the test above the ‘floor’ level, it may prove to be a useful 
neuropsychological test of associative memory in the ID population.  
 
There is limited research examining how people with ID perform on 
neuropsychological tests of memory. Of the evidence available, people with 
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mild ID have been shown to have more difficulty on tests of free recall than 
on tests of recognition (e.g. Martin et al. 2000; Van der Molen et al. 2010). For 
example, Martin et al.’s (2000) study of adults’ (aged 19-58 years) 
performance on the Rivermead Behavioural Memory Test showed that 
people with mild ID (FSIQ 55-75) performed best on tasks of visual memory 
and that they found verbal recall the most difficult. Van der Molen et al. 
(2010) confirmed these findings in their sample of young adults (aged 13-
17years) with mild ID (FSIQ 55-75). They found that verbal recall was poorer 
compared to matched controls and those with ID showed a strength in visual 
recognition.  
 
A recent meta-analysis (Lifshitz et al. 2011) found that performance on recall 
and recognition tasks can be improved in people with ID by increasing the 
depth of processing (e.g. asking participants to name the object to be recalled 
as this improves semantic encoding) as well as using the visual modality 
rather than verbal modality. Therefore, the VAT may be a useful tool given 
that it incorporates these features. It is also a cued recall test, which should 
be an area of strength for people with ID due to their performance on 





The aim of the present exploratory study was to conduct a preliminary 
examination of the psychometric properties of the VAT to help determine if it 
was a suitable measure of memory in adults with ID. It was hypothesised 
that participants in this current study would score between four and six on 
the VAT as this is consistent with performance in the general population, 
whereby those without any impairment generally perform near or at the 
ceiling of the test (Lindeboom & Schmand 2008). This includes an 
examination of one aspect of construct validity, namely convergent validity, 
of the VAT with the adapted CAMCOG-DS (Ball et al. 2006). This is 
following research which has examined the relationship between the VAT 
and CAMCOG in the general adult population (Lindeboom et al. 2002).  
 
The current study had additional aims including examining the relationship 
between the VAT and all subtests of the WAIS-IV in order to investigate the 
psychometric properties of the VAT further. There was insufficient 
information to make an a priori hypothesis. Additionally, the effect of IQ, age 
and gender on VAT performance will be examined given the exploratory 
nature of this study. Furthermore, the reliability of the VAT will be examined 





The following hypotheses were explored: 
Hypothesis 1: Participants will score between four and six on the VAT 
(Trial 1). 
Hypothesis 2:  There will be a significant positive correlation between 
performance on the VAT and the picture recall and 





















A cross-sectional, correlational design was adopted to examine the 
performance of a sample of participants with mild-moderate intellectual 
disabilities on the Visual Association Test (Lindeboom & Schmand 2008).  
The study was granted approval from the South East of Scotland Research 
Ethics Committee.  
 
Participants 
Of the potential participants that the researcher met: four could not provide 
informed consent; two participants did not meet the inclusion criteria; seven 
participants decided not to take part; and one participant asked to stop after 
the first trial of the VAT. The final sample consisted of 40 adults (21 males 
and 19 females) aged between 18 to 44 years (mean age 31.08 years; SD 8.075) 
with mild-moderate ID (mean FSIQ 59.10, SD 7.57; range 46-73). All 
participants were of mixed aetiology including: Down syndrome; Prader-
Willi syndrome; Fragile X syndrome; Velocardiofacial syndrome; and ID (not 






In order to be eligible for inclusion, all potential participants had to be 
between 18 and 45 years of age; fluent in English; and able to provide 
consent. Potential participants were excluded if they had: significant visual 
or hearing impairments; a diagnosis of dementia; significant personality and 
behavioural problems or a severe ID.    
 
Participants were recruited via health professionals from Community 
Learning Disability Teams based in the North of Scotland. Those who were 
interested in participating were subsequently contacted by the researcher, 
who provided further details about the study.  
 
Information was provided in an accessible format and this was reviewed at a 
focus group for people with ID prior to commencement of the study. 
Accessible information was provided to enable potential participants to 
make informed decision regarding participation in the study. BPS guidelines 
and other relevant guidelines of assessing for consent were adhered to (BPS 
2010; Dobson 2008). Consent was gathered by means of a written consent 
form which was witnessed by their clinician or relative to ensure consent was 
acquired appropriately. However, consent was viewed as an ongoing process 





Visual Association Test 
The Visual Association Test (VAT; Lindeboom et al. 2002) consists of six 
cards depicting line drawings of interacting objects (e.g. an ape holding an 
umbrella) and six cards depicting only one of the objects as a cue. The VAT is 
valid and reliable with an internal consistency of 0.84 on the first trial and 
0.86 for those who completed two trials on Form A (Lindeboom and 
Schmand 2008). Its validity has been replicated by others (e.g. Diercks et al. 
2007; Henneman et al. 2009; Kulansky et al. 2002). In the current study, 
Cronbach’s alpha was 0.41 for the first trial and 0.66 for the two trials. An 
acceptable value of alpha is above .7 (see Pallant 2010).   
 
Intellectual Functioning 
The Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV; Wechsler 
2008) was used to assess intellectual functioning. It includes a broad battery 
of subtests and has excellent psychometric properties. The WAIS-IV was 
normed on a large sample of individuals (n = 2200) of adults between the age 
of 16-90 years. The WAIS-IV is both reliable and valid with an internal 
consistency of 0.98 for the Full Scale IQ. It has been shown to be a strong 
measure of intelligence (e.g. Canivez & Watkins 2010). 
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Cambridge Cognitive Examination adapted for people with Down Syndrome and 
Intellectual Disabilities  
Visual incidental learning was also measured using the picture recall and 
picture recognition subtests of the modified Cambridge Cognitive 
Examination, CAMCOG-DS. These subtests on the CAMCOG have been 
shown to correlate with the VAT in the general population (Lindeboom et al. 
2002). The CAMCOG-DS is the neuropsychological section of the CAMDEX-
DS (Ball et al. 2006) which was adapted for use with people with DS and ID. 
Although validity for the CAMCOG-DS has not yet been established, the 
CAMCOG has been shown to be reliable and has excellent internal reliability. 




All participants were administered the neuropsychological tests in the same 
order: (1) VAT; (2) WAIS-IV (if applicable) and (3) Sub-tests from CAMCOG-
DS.  If the WAIS-IV assessment had been previously completed, this was not 
repeated.  A break of 20 minutes between the administration of the VAT and 
the CAMCOG-DS was provided to reduce the likelihood of participants 




The standardised protocols were followed for administration of the WAIS-IV 
and CAMCOG. Adaptations were made to the administration of the VAT;   
Form A was used, which involved two trials which are suitable for ‘younger 
but poorly testable patients’ (Lindeboom & Schmand 2008, pp. 27) in 
conjunction with  the instructions from form B as these were deemed to be 
easier for those with ID to understand. Testing lasted between thirty minutes 
and two hours and breaks were also provided. A second appointment was 
provided for individuals completing the WAIS-IV.       
 
VAT Administration  
In the first trial, the six cards of interacting objects were presented. The 
participants are asked to name the associated objects to maintain attention 
(i.e. frying pan and dice). The cue cards (showing only one of the objects) 
were then presented without delay. Participants were asked, ‘what object is 
missing?’ For example, ‘what was in the frying pan?’. Reponses were 
accepted and awarded one point if they were clear in differentiating between 
the target object (e.g. dice) with the other objects presented in the test. 
Acceptable responses were allowed to be spoken, written, illustrated or 
imitated. The points from the two trials were then totalled awarding a 
maximum score of 12 points for the test. The second trial is only commenced 
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if participants score less than the maximum score of six on the first trial, 
otherwise, full points are awarded for the second trial.  
 
CAMCOG Subtests Administration  
Initially, participants were asked to name the pictures of everyday objects 
(e.g. shoe, computer and scales). Participants were asked to recall the names 
of the objects following a delay. There was then followed by a recognition 
trial whereby participants were presented with the pictures of the objects 
they had seen and other similar objects (e.g. three shoes). They were then 
asked to identify which object they had seen before. Each subtest awards six 
points.  
 
Rationale for Data Utilised in the Current Study 
The aim of this study is to examine the properties of the VAT in a sample of 
participants without dementia. In order to examine this, the data from VAT 
Trial 1 will be used as it examines whether items have been associated or not 
in memory. That is, to see if the target and the cue are perceived as one object 
and with a cue provided whether the target is accurately recalled. It is 
believed that Trial 2 examines whether participants can learn after a repeated 
trial and thus demonstrate an incidental learning effect. Thus, it is expected 
by the authors of the VAT that performance will improve on Trial 2 (if this is 
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administered). Given that the purpose of the paper is to determine whether 
the VAT has convergent validity with other similar tests, Trial 1 will be used 
as the picture recall subtest (CAMCOG-DS) only involves one learning trial. 
Using the Trial 2 data could potentially confound the results due to the 






















Data were screened to assess for normality, homogeneity of variance, skew 
and kurtosis to ensure agreement with statistical assumptions. Violations of 
normality were found for the VAT, CAMCOG-DS and WAIS-IV following 
visual inspections of the histograms and Q-Q plots. This was confirmed by 
Shapiro-Wilk’s test. This test was used as it is more accurate than its 
counterpart, Kolmogorov-Smirnov, when samples are smaller (Field 2009). 
Although recommended, the distributions were not transformed in order to 
use parametric analysis (see Tabachnick & Fidell 2001). Instead, non-
parametric analysis was used as the intention was to simplify the 
interpretation of the findings. Furthermore, given that the VAT scores are 
categorised on an ordinal scale, using non-parametric tests was more 
appropriate (Field 2009). The raw scores of tests were used rather than 
transforming scores into a common metric such as t scores (Crawford 2004).  
As multiple correlations are being carried out, a Bonferroni calculation was 
considered in order to reduce the likelihood of a type one error, however, 
this was deemed to be too conservative and would increase the likelihood of 





Table 1 presents the participants’ scores on all the neuropsychological tests 
and the mean and median score and standard deviation. 
 
Table 1. Means and Standard Deviations of Test Scores (n=40). 
Test  Mean SD Range Median  Max 
Score 
VAT Trial 1 5.7 0.61 (4-6) 6 6 
 Total 2 trials 11.6 0.90 (8-12) 12 12 
CAMCOG-
DS 
Picture recall 1.95 1.84 (0-6) 1 6 
 Picture recognition 5.65 0.74 (4-6) 6 6 
WAIS-IV FSIQ 59.10 7.57 
 
(46-73) 59 160 
Subtests Arithmetic 3.55 1.50 (1-8) 4 19 
 Block Design 3.93 2.30 (1-10) 4 19 
 Coding 3.20 2.02 (1-9) 3 19 
 Digit Span 3.68 2.33 (1-10) 4 19 
 Information 4.83 1.90 (3-11) 4 19 
 Matrix Reasoning 3.75 1.53 (1-7) 3 19 
 Similarities 4.00 1.63 (1-7) 4 19 
 Symbol Search 3.35 2.12 (1-9) 3 19 
 Visual Puzzles 4.55 1.20 (2-7) 5 19 













Hypothesis 1: Participants will score between four and six on the VAT (Trial 
1). 
 
Table 2. Distribution (in %) in Memory Test scores (n=40) 
Test score 0 1 2 3 4 5 6 
CAMCOG-DS picture recall 55.0 22.5 10.0 12.5 10.0 15.0 0.0 
CAMCOG-DS picture 
recognition 
0.0 0.0 0.0 5.0 0.0 20.0 75.0 
VAT (1 trial) 0.0 0.0 0.0 0.0 7.5 15.0 77.5 
 
As can be seen from the descriptive data shown in Table 2 participants’ 
scores ranged from four to six. This supports the prediction made.  
 
Hypothesis 2: There will be a significant positive correlation between 
performance on the VAT and picture recall and picture recognition subtests 
of the Cambridge Cognitive Examination for people with DS and ID 
(CAMCOG-DS; Ball et al. 2006). 
 
As can be seen from the descriptive data in Table 1, 55 per cent of 
participants scored at the ‘floor’ of the recall subtest of the CAMCOG-DS. No 
significant relationship was found between performance on the VAT Trial 1 
and picture recall (T=0.005, p=.974). However, the majority of participants 
(75%) obtained full marks for the picture recognition trial. Nevertheless, no 
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significant relationship was found between performance on the VAT Trial 1 
and picture recognition (T=0.82, p=.595).  
 
Relationship between VAT, IQ, age and gender 
In order to determine if performance on the VAT was affected by the degree 
of intellectual disability (IQ), age or gender, a series of analyses were 
conducted to examine this.  
 
Kendall’s Tau (non-parametric) test was used to correlate VAT scores with 
IQ and age. Field (2009) argued that this test should be employed with small 
samples where there are scores with comparable ranks. Furthermore, it is a 
more accurate representation of correlations in the population which should 
lead to better generalisations to the real world (e.g. Clark-Carter 2010; Field 
2009). No significant correlations were found between the VAT (Trial 1) and 
IQ (T=0.84, p=.520); nor between the VAT (Trial 1) and age (T= -0.35, p=.784) 
as tested by Kendall’s Tau. Furthermore, the Mann-Whitney U test revealed 
no significant differences between males and females on the VAT (Trial 1) 






Relationship between VAT and WAIS-IV subtests 
The relationship between the VAT and WAIS-IV subtests were conducted to 
examine the psychometric properties of the VAT further. No correlations 
were found between the VAT (Trial 1) and any of the WAIS-IV subtests at 
p<0.01 (Arithmetic t=.302; Block design t=.142; Coding t=.085; Digit span t=-
.700; Information t=.107; Matrix reasoning t=.059; Similarities t=.265; Symbol 

















This research study examined the convergent validity of the Visual 
Association Test (VAT) in 40 adults with mild-moderate intellectual 
disabilities (ID). Firstly, as was predicted, the participants scored between 
four and six on the VAT. No participants scoring at the ‘floor’ level and 77.5 
per cent obtaining the maximum score. This is consistent with the general 
population, whereby those without any impairment generally perform at or 
near the ceiling of the test (Lindeboom & Schmand 2008). The present study 
also found that performance on the VAT was not affected by age, IQ or 
gender. These findings are also consistent with the literature examining 
performance on the VAT in the general adult population (Lindeboom et al. 
2008). These findings highlight that the VAT could be a potentially useful 
neuropsychological tool for people with ID. Furthermore, the VAT may 
prove to be useful in the assessment of dementia given that participants 
scored highly on the test, indicating scope for demonstrating change on the 
test. Neuropsychological tests that have been used in the general adult 
population when applied with people with ID often result in ‘floor’ effects 





The VAT has been found to correlate with the memory items of the 
CAMCOG in the general population (Lindeboom et al. 2002), however the 
present study found no significant relationship between the VAT and picture 
recall and recognition subtests of the CAMCOG-DS. The former result may 
be because people with ID have difficulties with tasks of free recall (e.g. 
Martin et al. 2000; Van der Molen et al. 2010). Additionally, the validity of the 
CAMCOG-DS is yet to be established and this may be another reason for not 
finding a relationship. With regard to the picture recognition subtest, 
descriptively participants performed similarly on this and the VAT, with 75 
per cent of participants obtaining a score of six on recognition and 77.5 per 
cent of participants obtaining a score of six on the VAT. This suggests that 
the VAT may show convergent validity in this population, however, a 
statistically significant correlation was not found. One of the reasons for this 
may be because there was a limited range of scores on all of the tests in this 
study, with most participants performing at the ceiling of the test, scoring 
between four and six (total score 0-6). Nevertheless, the findings have 
demonstrated that participants with ID performed better on tasks of 
recognition and cued recall than on tasks of free recall which is supported by 
the literature (e.g. Martin et al. 2000; Van der Molen et al. 2010). This suggests 




Further analysis of the data with regards to the psychometric properties of the 
VAT showed that there were no correlations between the VAT and subtests of 
the WAIS-IV. This provides some support for the VAT being conceptually 
different than the requirements of the subtests of the WAIS-IV. This highlights 
that the VAT is primarily assessing memory rather than another cognitive 
function (i.e. processing speed). It also lends support for the VAT tapping into 
different regions of the brain than the WAIS-IV subtests. Unlike the VAT, none 
of the WAIS-IV subtests have been allied with the medial temporal lobes. For 
example, the digit span subtest of the WAIS has been related to the prefrontal 
cortex region (Kanecho et al., 2011). However, the VAT has been shown to have 
a relationship with atrophy in the medial temporal lobes (Lindeboom & 
Schmand, 2008). Further research is needed to substantiate this using functional 
MRI within the ID population.  
 
The reliability of the VAT was examined, however, the value of alpha was 
poor. There are several potential reasons for this finding. Firstly, it may be 
due to the small sample size in this study. Secondly, Cronbach’s alpha can 
also be sensitive to the number of items in the scale (Pallant 2010). Lastly, the 





Strengths & Limitations of Study 
One of the strengths of this study was that it included participants with a 
variety of genetic conditions (e.g. Down syndrome, Fragile X, Prader Willi 
syndrome) all of whom obtained high marks on the VAT. It is of note that the 
two adults with DS included in the study obtained full marks on the VAT. 
People with DS have an increased risk of developing AD than the general 
population (e.g. Tyrell et al. 2001), therefore, finding tests that are sensitive to 
changes in memory, particularly paired associates tasks, is of extreme 
importance, as it is argued that they are more sensitive to changes in the 
hippocampus (e.g. Henneman et al. 2009). This exploratory study suggests 
that the VAT is one such test that could have potential in this area, as well as 
being applicable to a range of adults with ID. However, further research is 
needed to corroborate these findings with larger samples. 
 
A limitation of the study is that the variety of genetic conditions in the 
participant sample means that the group was not homogenous and thus, the 
study does not provide norms for a specific group. It is therefore, not clear 
what factors may have moderated or mediated performance on the VAT. 
While the study found no relationship between performance on the VAT and 
age, gender and level of ID, the study did not control for other factors that 
have been found to confound test results, such as health conditions (e.g. Burt 
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et al. 1992; Das et al. 1995; Devenny et al. 1996; Hanney et al. 2009). Further 
research with larger sample sizes is needed to explore these potential 
relationships further.    
 
The present study provided a useful examination of the VAT with people 
with ID, however it is limited in that it has only focused on convergent 
validity and reliability when examining the psychometric properties of the 
VAT. Future studies which explore additional forms of validity and 
reliability of the VAT with this population are needed.  
 
Another limitation of the study is the relatively small number of participants. 
This is likely to have impacted on the statistical power of the study. For 
example, research has found that other neuropsychological tests are 
influenced by IQ, such as the California Verbal Memory Test (CVLT; Rapport 
et al. 1997), whereas the present study found no relationship between IQ and 
performance on the VAT. It is unclear, whether this result is an artefact of the 
relatively small sample size. 
 
Future Research & Clinical Implications 
It is premature to suggest that the VAT can be used as a test of associative 
memory in people with mild-moderate ID as the psychometric properties of 
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the VAT requires further examination. Future research could examine the 
psychometric properties of the VAT in larger homogenous samples, 
specifically with adults with DS, given their increased risk of developing AD. 
This would be beneficial as a multi-site research project and it would 
increase the generalisability of the findings. Future research could then 
examine the application of the VAT in the assessment of AD in the DS and ID 
population. 
 
In addition to the psychometric properties examined, there are practical and 
clinical advantages of using the VAT in this population as it is simple, quick 
to complete and it was well received by all of the participants. Furthermore, 
given the lack of available memory tests for the ID population (Masson et al. 
2010), the VAT has potential to be a welcome addition to the tests available.  
 
Conclusion 
This research study has shown that the majority of participants with ID 
scored highly on the VAT. Additionally, their performance was not affected 
by IQ, age or gender. However, the aim of this study was to examine the 
convergent validity of the VAT with the CAMCOG-DS but this was not 
demonstrated. Further research is therefore needed to determine if the VAT 
represents a useful assessment tool with this population by investigating its 
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validity in a larger sample. Following this, the ability of the VAT to screen for 
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CHAPTER 4: EXTENDED METHODOLOGY 
 
4.1. Design 
A cross-sectional, correlational design was adopted to examine a sample of 
participants with mild-moderate intellectual disabilities (ID) performance on 
the Visual Association Test (VAT).  Correlational analysis was employed to 
compare the VAT with two subtests of the modified Cambridge Cognitive 
Examination (CAMCOG-DS; Ball et al. 2006). The relationship between Full 
Scale IQ scores (as measured by the Wechsler Adult Intelligence Scale, forth 
edition, WAIS-IV; Wechsler 2008) age, gender, and the VAT, were also 
correlated. The independent variable was the presence of ID and the 
dependent variables were objective measures of memory. 
 
4.1.1 Ethical approval 
The study was appraised by the University of Edinburgh’s academic staff. 
Ethical approval was permitted by NHS Lothian Research Ethics Committee 
(Appendix 6). Management approval was granted from NHS Highland and 






4.1.2 Ethical considerations: Method of recruitment  
Given that this study involved vulnerable adults, the recruitment of 
participants was accessed through clinicians already involved in their care. 
Staff were provided with an information sheet about the study (Appendix 
10). All participants were aged between 18 and 45 years. Potential 
participants were provided with participant information booklets (Appendix 
9 and Appendix 10) by clinicians already involved in their care and if willing 
to participate either contacted the researcher directly or asked their clinician 
or carer to do this. When they met with the researcher, potential participants 
were able to ask questions about the research prior to deciding whether to 
take part. An independent contact was available for people to contact as well. 
It was made clear that participation in the study was voluntary and that they 
could withdraw at anytime without having to give a reason. It was also 
emphasised that declining to participate at any point would have not affect 
their current care or future treatment. All participants were offered an option 
of receiving written feedback regarding their results after completion of the 
tests.    
  
4.1.2.1 Ethical considerations: Development of participant information 
As this study involved people with ID, time was taken to develop participant 
information in accessible formats. Two information sheets were developed: 
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one provided more detailed written information and the second was 
presented in a booklet form which contained both pictures and words 
(Appendix 9 and 10). The sheets were developed to provide the information 
in an accessible, east to read format in line with standards (e.g. Inclusion 
Europe (n.d.); Scottish Accessible Information Forum 2001). An Accessible 
Information Officer in the Learning Disabilities Service reviewed this 
information at a focus group for people with ID prior to the study’s 
commencement. The information was developed to provide accessible 
information in different formats to enable potential participants to make 
informed decisions regarding participation in the current study.  
 
4.1.2.2 Ethical considerations: Consent to research 
This study only included people who could provide informed consent. 
Nevertheless, the researcher was aware that there can be difficulties ensuring 
that people with ID can fully consent to participating in research (Cameron & 
Murphy 2006). For that reason, the British Psychology Society guidelines of 
conduct were adhered to (BPS 2010) and other guidance documents were 
considered (see Dobson 2008). In addition, the researcher discussed ways of 
communicating information with the Speech and Language Therapist in the 
Learning Disabilities Service prior to commencement of the study. This was 
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done in order to ensure that potential participants could understand the 
research and its consequences fully.  
 
A witness, either a relative or clinician involved in the person’s care was also 
present to ensure that consent was assessed appropriately. Potential 
participants were deemed to be able to consent if they could: understand the 
research study; the pros and cons of participating; communicate their 
decision; knew their participation was voluntary and that they could 
discontinue at any point. The researcher was aware that people might agree 
to participate without fully comprehending the implications (Arscott et al. 
1998). In addition, the researcher paid attention to non-verbal cues as 
indicators of giving consent, such as eye-contact and body-language in 
addition to verbal responses (Cameron & Murphy 2006). Consent was 
gathered by means of a written consent form (Appendix 12). However, the 
researcher perceived consent as an ongoing process and therefore reminded 
participants prior, during and after testing that they could discontinue at any 
point without having to give a reason.  
 
4.1.2.3 Ethical considerations: Psychological distress 
It was recognised that the research process may uncover a clinical problem 
which had not been diagnosed. Therefore, consent was sought prior to 
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participation in the study for the researcher to contact the participants’ 
General Practitioners if required.  
 
4.1.2.4 Ethical Considerations: Fatigue 
Participation in the study involved completing neuropsychological 
assessments for a period of thirty minutes to a maximum of two hours. All 
participants were therefore offered breaks during testing and further 
appointments were arranged if participants became fatigued.  
 
4.2 Participants 
All potential participants were: able to provide consent, aged between 18 and 
45 years of age, and fluent in English. Potential participants were excluded if 
they had: a diagnosis of dementia; a severe ID; significant personality and 
behavioural problems; significant visual or hearing impairments. 
Participants were not excluded on the basis of general medical conditions 
such as diabetes, epilepsy, and high blood pressure. Instead, these were 
noted from participants’ medical files with their consent.  
 
Participants were recruited through contacting health professionals from 
Community Learning Disability Teams. The researcher met the teams and 
asked then to recommend people eligible to participate. Clinicians were 
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provided with further information about the study (Appendix 11). The 
clinician involved with the potential participant contacted them in the first 
instance and provided them with an information booklet (Appendix 9 and 
Appendix 10). Clinicians contacted the researcher with the details of those 
who agreed to find out more about the study. The researcher contacted 
potential participants and arranged an appointment. Information was 
provided about the study and an opportunity was given to ask questions 
about the study and discuss any concerns. A minimum of 24 hours was given 
to allow participants to consider whether to participate. A further 
appointment was offered at a location of their choice, either at their home or 
at a clinic. Those who agreed to participate and who were able to provide 
informed consent were provided with a written consent form (Appendix 12). 
Each item on the form was discussed by the researcher. For the majority of 
participants a clinician, family member or support worker was available to 
witness that consent had been gathered appropriately. However, the 
researcher put emphasis on the fact that participants could withdraw their 
consent at any time without having to give an explanation. Demographic 






4.2.1 Participant sample 
There were a number of participants approached by clinicians who decided 
not to meet the researcher to hear more about the study. Unfortunately, 
clinicians did not provide exact numbers on how many people declined. 
Therefore, the exact response rate could not be calculated. Of the information 
that was available, 18 people who were approached did not wish to meet the 
researcher. Of the potential participants that the researcher met: four could 
not provide informed consent; seven decided not to take part; two did not 
meet the inclusion criteria; and one participant asked to stop after the first 
trial of the VAT. The final sample consisted of 40 adults (21 males and 19 
females) aged between 18 to 44 years (mean age 31.08 years; standard 
deviation, SD, 8.075) with mild-moderate intellectual disabilities (mean FSIQ 
58.80; SD 7.930 range 46-73).  
 
Consent was gathered to obtain participants’ medical files. Of the 40 
participants, 12 had specific conditions including: Cerebral Palsy (n=3); 
Down syndrome (n=2); Foetal alcohol syndrome (n=1); Fragile X syndrome 
(n=1); Prader-Willi syndrome (n=2); Rubenstein Taybi syndrome (n=2); 




Participants had a range of medical and health diagnoses including: adhd; 
anxiety; autism; diabetes; epilepsy; fallot tetralogy; heart problems; myotonic 
dystrophy; scoliosis; and velocariofacial syndrome. The variety of conditions 
and related health diagnoses indicates that this is a clinical sample.  
 
4.2.2 Sample size  
Most studies have completed population studies and have not reported effect 
sizes or power calculations. The closest study which provides a rationale for 
the current proposed study was by Masson et al. (2010). They studied the 
correlations between the Tower of London test which measures executive 
functioning, with measures such as Wechsler Abbreviated Scale of 
Intelligence (WASI; Wechsler 1999), the Dysexecutive Questionnaire – 
Independent Rater (Burgess et al. 1996) and the Adaptive Behaviour Scale – 
Residential and Community: Second Edition (ABSRC:2; Nihira et al. 1993). 
They used a medium to large effect size of .40, set the alpha at .05 and aimed 
to recruit a sample size of 50, to provide power of .821. The study included 
43 individuals with intellectual disability. It was calculated that Masson et al. 
(2010) had a large effect size in their study. 
 
This study was used to determine the sample size for the current study. A 
power analysis program called G*Power3 (Faul et al. 2009) was used to 
113 
 
calculate the minimum number of participants necessary to detect a large 
effect size using correlations. A significance level of .05, at a power of .80 and 
with a large effect size .50, would require a minimum sample of 26 people to 
be included in the current study. However, given that the current study is 
examining memory, this empirical study applied a medium-large effect size 
which would require a minimum sample of 44 people. 
 
Given that this study is exploratory and is examining the utility of a 
neuropsychological test in this population, the sample size is more than 
adequate for this purpose. Many research studies examining the utility of 
neuropsychological tests have not calculated effect sizes as they have 
examined performance on the measure prior to a larger research study being 
completed (e.g. Rivermead Behavioural Memory Test, Children’s Version, 
RBMT-C; Hon et al. 1998).  In this study, there were a total of 40 participants 




4.3.1 Demographic characteristics 
Basic information including age and gender were collected from the 
participants. Consent was acquired from participants to access their medical 
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records about any pre-existing medical conditions that may have impacted 
on their cognitive ability and neuropsychological testing. For example, 
depression and hyperthyroidism (Burt et al. 1992; Das et al. 1995; Devenny et 
al. 1996) and visual or hearing impairments (e.g. Hanney et al. 2009).  
Consent was also obtained to access the participants’ psychology files for 
recent intellectual functioning assessment reports, specifically the Wechsler 
Adult Intelligence Scale, 4th Edition (WAIS-IV; Wechsler 2008).   
 
4.3.2 Neuropsychological tests  
The main aim of the research study was to examine the utility of the Visual 
Association Test (VAT) with adults with ID and to determine whether it is a 
suitable measure for adults with ID.  In addition to this other tests were 
employed: WAIS-IV (Wechsler 2008) and two subtests of the Cambridge 
Cognitive Examination adapted for people with Down syndrome and 
intellectual disabilities (CAMCOG-DS; Ball et al. 2006). These were employed 
to assess intellectual functioning and visual incidental learning respectively.  
These neuropsychological tests will be examined and discussed in detail.     
 
4.3.2.1 Visual Association Test (VAT; Lindeboom et al. 2002, 2008) 
The VAT is a brief test of visual paired-associates learning based on imagery 
mnemonics. The VAT is a measure of episodic memory and is a visuo-spatial 
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cued recall task. It consists of six pairs of interacting objects presented as line 
drawings. The participant is asked to the name the interacting objects then 
one of the objects is presented as a cue and the participant is asked to name 
the missing object. One point is awarded for each correct response. A 
maximum of six points are awarded. This procedure is then repeated for a 
second trial and a total of 12 points are awarded overall. The test predicts 
that the visual associated objects will be learned effortlessly and failure to do 
so is a result of problems with the encoding of new information. Thus the test 
was intended to detect anterograde amnesia and related disorders.  
 
4.3.2.1.1 VAT: Reliability  
The reliability of the VAT has been examined in terms of internal 
consistency, test-retest and parallel test reliability (see Lindeboom & 
Schmand 2008). The VAT has demonstrated good internal consistency. Form 
A, Cronbach’s Alpha was 0.84 on the first trial and 0.86 for those who 
completed two trials. Test-retest reliability has been demonstrated for Form 
A. Parallel test reliability was examined by correlating Form A and B with 
177 patients from Vrije University and demonstrated 0.74 and 0.84 for Trial 1 





4.3.2.1.2 VAT: Validity 
Validity was studied by the authors, Lindeboom and Schmand (2008), 
namely construct, discriminative, criterion and concurrent validity. 
Confounding influences were also examined.  The VAT demonstrated good 
construct validity and correlates highly with the Cambridge Cognitive 
Examination (CAMCOG; Huppert et al. 1995; Roth et al. 1986). The VAT has 
high discriminative validity and can distinguish between people with 
Alzheimer’s disease (AD) and healthy older people (Kulansky et al. 2002). 
This has been replicated by Dierckx et al. (2007) whereby the VAT classified 
those with AD, depression and healthy people correctly. Criterion validity 
was established by Lindeboom and Schmand (2008) who found a significant 
association with atrophy of the medial temporal lobes and low VAT-scores 
(p=.007). This has been replicated by other researchers (Henneman et al. 
2009). The relationship between informal judgement of a subject’s memory 
and VAT scores were also examined by the authors. They found a significant 
correlation (p<.001) between severe memory problems and low VAT scores. 
Concurrent validity was established by correlating the VAT Form A and 
CAMCOG sections on memory. The sum of memory and orientation 
subscales reached the highest correlations (i.e. .64, p<.00001) with the VAT. 
Confounding influences were examined and demonstrated that the VAT is 
not significantly associated with age, sex, educational achievement or 
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depression. Overall, the VAT is a highly reliable and valid test. Its high 
specificity in distinguishing AD has been demonstrated elsewhere (e.g. 
Dierckx et al. 2007; 2009; Fuchs & Pentxek 2011).   
 
4.3.2.2. Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV; Wechsler 
2008) 
The WAIS-IV was used as an assessment of cognitive ability. It includes a 
broad battery of subtests and has excellent psychometric properties. The 
WAIS-IV was normed on a large sample of individuals (n=2200) of adults 
between the age of 16-90 years. The WAIS-IV is both reliable and valid with 
an internal consistency 0.98 for the Full Scale IQ. It has been shown to be a 
strong measure of intelligence (e.g. Canivez & Watkins 2010). 
 
4.3.2.3 Picture Recall and Picture Recognition: Cambridge Cognitive Examination, 
CAMCOG-DS (In Cambridge Examination for Mental Disorders of Older People 
with Down’s Syndrome and Others with Intellectual Disabilities, CAMDEX-DS; 
Ball et al. 2006) 
Originally, the CAMDEX was developed as a standardised assessment tool 
for use in the general elderly population for diagnosis of mental disorders, 
and more specifically for the detection of dementia (Huppert et al. 1995; Roth 
et al. 1986). The CAMDEX was modified for use with people with Down 
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syndrome and intellectual disabilities (Ball et al. 2004) in response to the 
need for suitable and valid measures of dementia in this population (Holland 
& Ball 2009).    
 
The schedule consists of a number of useful assessment tools including a 
neuropsychological test battery, the Cambridge Cognitive Examination 
(CAMCOG). The CAMCOG measures the cognitive functions known to 
deteriorate in dementia. The structure of the CAMCOG-DS is the same as the 
CAMCOG with some modifications to make the tests suitable for people 
with intellectual disabilities. Hon et al. (1999) demonstrated that the 
CAMCOG could be used with people with Down syndrome and intellectual 
disabilities with some modifications (i.e. CAMGOG-DS). It correlates well 
with Mini Mental State Examination (MMSE; Folstein et al. 1975) and only a 
small percentage of their participants scored at the floor of the test (11%). 
Although validity for the CAMCOG-DS has not yet been established, the 
CAMCOG has been shown to be reliable and has excellent internal reliability. 
Cronbach’s alpha was 0.82 and 0.89 in different samples. The test-retest 
reliability is excellent with a Pearson’s correlation of 0.86 (Huppert et al. 
1996; Holland & Ball 2009). The findings have been replicated by other 
studies, and demonstrate that the CAMCOG has high sensitivity and 
specificity for the diagnosis of dementia (e.g. Lindeboom et al. 1993).  
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The picture recall and picture recognition subtests of the CAMCOG-DS were 
administered as another test of visual incidental learning similar to the VAT. 
These subtests on the CAMCOG have been shown to correlate with the VAT 
in the general population (Lindeboom et al. 2002). 
 
Recall and recognition are two main retrieval processes which allow 
clinicians to test how information has been stored (Baddeley 2004). Picture 
recall asks participants to recollect what pictures they have seen previously 
following a delay. One point is awarded for each correctly recalled item. A 
maximum of six points can be achieved. Picture recognition asks participants 
to point to the picture they saw previously from three pictures, only one of 
which the participant saw previously. Similarly, one point is awarded for 
each correctly identified picture. A maximum of six points can be achieved.  
 
Efforts were made to collect information on the performance of people with 
DS and ID on the CAMCOG-DS from the authors of the epidemiological 
study (Hon et al. 1999). However, this information was not received prior to 






4.4 Procedure  
4.4.1 Administration  
All participants were administered the neuropsychological tests in the same 
order: (1) VAT; (2) WAIS-IV (if applicable) and (3) Sub-tests from CAMCOG-
DS.  If the WAIS-IV assessment had been previously completed, this was not 
repeated.  A break of 20 minutes between the administration of the VAT and 
the CAMCOG-DS was provided to reduce the likelihood of participants 
confusing the test items from each test.  
 
The standardised protocols were followed for administration of the WAIS-IV 
and CAMCOG-DS. Adaptations were made to the administration of the 
VAT; Form A was used, which involved two trials which are suitable for 
‘younger but poorly testable patients’ in conjunction with  the instructions 
from Form B as these were deemed to be easier for those with an intellectual 
disability to understand (Lindeboom & Schmand 2008, pp 27). Testing lasted 
between thirty minutes and two hours and breaks were also provided. A 
second appointment was provided for individuals completing the WAIS-IV. 
Participants were given the option of requesting written comments on their 







Arscott K., Dagnan D. & Kroese B.S. (1998) Consent to psychological research 
by people with an intellectual disability. Journal of Applied Research in 
Intellectual Disabilities 11, 77-83.  
 
Baddeley A. D. (2004) The Psychology of Memory. In: The Essential Handbook 
of Memory Disorders for Clinicians (eds A. D. Baddeley, M. D. Kopelman & B. 
A. Wilson), pp. 1-11. John Wiley & Sons, Ltd, West Sussex, England.  
 
Ball S., Holland T., Huppert F., Treppner P. & Dodd K. (2006) The Cambridge 
Examination for Mental Disorders of Older People with Down ’s syndrome and 
Others with Intellectual Disabilities, CAMDEX-DS. Cambridge University 
Press, Cambridge.  
 
Ball S.L., Holland A.J., Huppert F.A., Treppner P., Watson P. & Hon J. (2004) 
The modified CAMDEX informant interview is a valid and reliable tool for 
use in the diagnosis of dementia in adults with Down’s syndrome. Journal of 
Intellectual Disabilities Research 48, 611-20.  
 
British Psychological Society. (2010) Code of Human Research. BPS, Leicester. 
 
Burt D.B., Loveland K.A. & Lewis K.R. (1992) Depression and the onset of 
dementia in adults with mental retardation. American Journal on Mental 




Cameron L. & Murphy J. (2006) Obtaining consent to participate in research: 
the issues involved in including people with a range of learning and 
communication disabilities. British Journal of Learning Disabilities 35, 113-20.  
 
Canivez G.L. & Watkins M.W. (2010) Investigation of the factor structure of 
the Wechsler Adult Intelligence Scale – Fourth Edition (WAIS-IV): 
Exploratory and Higher Order Factor Analyses. Psychological Assessment 22, 
827-36.  
 
Das J.P., Divis B., Alexander J., Parrila R.K. & Naglierii J.A. (1995) Cognitive 
decline due to aging among persons with Down syndrome. Research in 
Developmental Disabilities 16, 461-478.  
 
Devenny D.A., Silverman W.P., Hill A.L., Jenkins E.A., Sersen E.A. & 
Wisniewski K.E. (1996) Normal ageing in adults with Down' syndrome: a 
longitudinal study. Journal of Intellectual Disability Research 40, 208-221.  
 
Dierckx E., Engelborghs S., De Raedt R., De Deyn P.P. & Ponjaert-
Kristoffersen I. (2007) Differentiation between mild cognitive impairment, 
Alzheimer’s disease and depression by means of cued recall. Psychological 
Medicine 37, 747-55.  
 
Dierckx E., Engelborghs S., De Raedt R., Van Buggenhout M., De Deyn P.P. & 
Verte D. (2009) Verbal cued recall as a predictor of conversion to Alzheimer’s 
disease in Mild Cognitive Impairment. International Journal of Geriatric 




Dobson C. (December 2008) Conducting research with people not having the 
capacity to consent to their participation: A practical guide for researchers. BPS, 
Leicester.  
 
Faul F., Erdfelder E., Buchner A. & Lang A. (2009) Statistical power analyses 
using G*Power 3.1: Tests for correlation and regression analyses. Behavior 
Research Method 41, 1149-60.  
 
Fuchs A., Wiese B., Altiner A., Wollny A. & Pentzek M. (2012) Cued recall 
and other cognitive tasks to facilitate dementia recognition in primary care. 
Journal of American Geriatrics Society 60, 130-5.  
 
Hanney M. L., Tyrer S. P. & Moore P. B. (2009) Overview of the 
Neuropsychological Assessment of Dementia in Intellectual Disability. In: 
Neuropsychological Assessments of Dementia in Down Syndrome and Intellectual 
Disabilities (ed V. P. Prasher), pp. 1-18. Springer-Verlag, London.  
 
Henneman W.J.P., Sluimer J.D., Barnes J., van der Flier W.M., Sluimer I.C., 
Fox N.C. et al. (2009) Hippocampal atrophy rates in Alzheimer disease. 
Neurology 72, 999-1007.  
 
Holland A. J. & Ball S. L. (2009) The Cambridge examination for mental 
disorders of older people with Down’s syndrome and others with intellectual 
disabilities (CAMDEX-DS) In: Neuropsychological Assessments of Dementia in 
Down syndrome and Intellectual Disabilities (ed V. P. Prasher), pp. 107-127. 
Springer-Verlag, London.  
124 
 
Hon J., Huppert F.A., Holland A.J. & Watson P. (1999) Neuropsychological 
assessment of older adults with Down’s syndrome: An epidemiological 
study using the Cambridge Cognitive Examination (CAMCOG). British 
Journal of Clinical Psychology 38, 155-65.  
 
Hon J., Huppert F.A., Holland F.A. & Watson P. (1998) The value of the 
Rivermead Behavioural Memory Test (Children's Version) in an 
epidemiological study of older adults with Down syndrome. British Journal of 
Clinical Psychology 37, 15-29.  
 
Huppert F.A., Brayne C., Gill C., Paykel E.S. & Beardsall L. (1995) CAMCOG 
- a concise neuropsychological test to assist dementia diagnosis: socio-
demographic determinants in an elderly population sample. British Journal of 
Clinical Psychology 34, 529-541.  
 
Huppert F.A., Jorm A.F., Brayne C., Girling D.M., Barkley C., Beardsall L. et 
al. (1996) Psychometric properties of the CAMCOG and its efficacy in the diagnosis 
of dementia. Aging, Neuropsychology, and Cognition 3, 201-14.  
 
Inclusion Europe (n.d.) Information for all: European Standards for making 
information easy to read and understand. Retrieved January 2012 from 
www.inclusion-europe.org 
 
Kuslansky G., Buschke H., Katz M., Silwinski M. & Lipton R.B. (2002) 
Screening for Alzheimer’s disease: the memory impairment screen versus the 
conventional three-word memory test.  Journal of the American Geriatric Society 




Lindeboom J., Horst R.T., Hooyer C., Dinkgreve M. & Jonker C. (1993) Some 
psychometric properties of the CAMCOG. Psychological Medicine 23, 213-219.  
 
Lindeboom J. & Schmand B. (2003) Visual Association Test: Manual. PITS, 
Leiden.  
 
Lindeboom J., Schmand B., Tulner L., Walstra G. & Jonker C. (2002) Visual 
association test to detect early dementia of the Alzheimer type. Journal of 
Neurology, Neurosurgery & Psychiatry 73, 126-33.  
 
Masson J.D., Dagnan D. & Evans J. (2010) Adaptation and validation of the 
Tower of London test of planning and problem solving in people with 
intellectual disabilities. Journal of Intellectual Disabilities Research 54, 457-67.  
 
Roth M., Tym E., Mountjoy C.Q., Huppert F.A., Hendrie H., Verma S. et al. 
(1986) CAMDEX: a standardised instrument for the diagnosis of mental 
disorder in the elderly with special reference to the early detection of 
dementia. British Journal of Psychiatry 149, 698-709.  
 
Scottish Accessible Information Forum (2001) A brief guide to making your 
information accessible. Retrieved January 2012 from  
http://www.saifscotland.org.uk/ 
 








1. Research in Developmental Disabilities (RIDD) author guidelines   
2. Search strategy 
3. Quality criteria adapted from Scottish Intercollegiate Guidelines 
Network (SIGN) 




5. Journal of Intellectual Disability Research (JIDR) author guidelines 
6. Ethical approval: Scotland A Research Ethics Committee 
7. Research & development approval: NHS Highland 
8. Participant (easy-read) booklet 
9. Participant information sheet 
10. Staff information sheet 












Submission to this journal proceeds totally online and you will be guided stepwise through 
the creation and uploading of your files. The system automatically converts source files to a 
single PDF file of the article, which is used in the peer-review process. Please note that even 
though manuscript source files are converted to PDF files at submission for the review 
process, these source files are needed for further processing after acceptance. All 
correspondence, including notification of the Editor's decision and requests for revision, 
takes place by e-mail removing the need for a paper trail. 
 
Peer review policy  
In order to maintain a rapid rate of review all submitted manuscripts are initially reviewed 
by the Editor in Chief for completeness and appropriateness to the journal's stated Aims and 
Scope. Manuscripts that pass the initial review will be handled by the Editor, sent out to 
reviewers in the field, sent to an associate editor for handling, or some combination thereof, 
solely at the discretion of the Editor. 
 
If for any reason you have questions about the peer review policy in general or with regards 
to your paper specifically, please address them directly to the Editor in Chief, Johnny 
Matson: johnmatson@aol.com. 
Use of wordprocessing software  
It is important that the file be saved in the native format of the wordprocessor used. The text 
should be in single-column format. Keep the layout of the text as simple as possible. Most 
formatting codes will be removed and replaced on processing the article. In particular, do 
not use the wordprocessor's options to justify text or to hyphenate words. However, do use 
bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table 
grid, use only one grid for each individual table and not a grid for each row. If no grid is 
used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way 
very similar to that of conventional manuscripts (see also the Guide to Publishing with 
Elsevier: http://www.elsevier.com/guidepublication). Note that source files of figures, tables 
128 
 
and text graphics will be required whether or not you embed your figures in the text. See 
also the section on Electronic artwork.  
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-
check' functions of your wordprocessor. 
 
Article structure  
Subdivision - numbered sections  
Divide your article into clearly defined and numbered sections. Subsections should be 
numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section 
numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the 




State the objectives of the work and provide an adequate background, avoiding a detailed 
literature survey or a summary of the results. 
 
Material and methods  
Provide sufficient detail to allow the work to be reproduced. Methods already published 
should be indicated by a reference: only relevant modifications should be described. 
 
Theory/calculation  
A Theory section should extend, not repeat, the background to the article already dealt with 
in the Introduction and lay the foundation for further work. In contrast, a Calculation section 
represents a practical development from a theoretical basis. 
 
Results  
Results should be clear and concise. 
 
Discussion  
This should explore the significance of the results of the work, not repeat them. A combined 
Results and Discussion section is often appropriate. Avoid extensive citations and discussion 
of published literature. 
 
Conclusions  
The main conclusions of the study may be presented in a short Conclusions section, which 





If there is more than one appendix, they should be identified as A, B, etc. Formulae and 
equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a 
subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. 
A.1, etc. 
 
Essential title page information  
• Title. Concise and informative. Titles are often used in information-retrieval systems. 
Avoid abbreviations and formulae where possible. 
• Author names and affiliations. Where the family name may be ambiguous (e.g., a double 
name), please indicate this clearly. Present the authors' affiliation addresses (where the 
actual work was done) below the names. Indicate all affiliations with a lower-case 
superscript letter immediately after the author's name and in front of the appropriate 
address. Provide the full postal address of each affiliation, including the country name and, 
if available, the e-mail address of each author. 
• Corresponding author. Clearly indicate who will handle correspondence at all stages of 
refereeing and publication, also post-publication. Ensure that telephone and fax numbers 
(with country and area code) are provided in addition to the e-mail address and the 
complete postal address. Contact details must be kept up to date by the corresponding 
author.  
• Present/permanent address. If an author has moved since the work described in the article 
was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be 
indicated as a footnote to that author's name. The address at which the author actually did 
the work must be retained as the main, affiliation address. Superscript Arabic numerals are 
used for such footnotes. 
 
Abstract  
A concise and factual abstract is required. The abstract should state briefly the purpose of 
the research, the principal results and major conclusions. An abstract is often presented 
separately from the article, so it must be able to stand alone. For this reason, References 
should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or 
uncommon abbreviations should be avoided, but if essential they must be defined at their 






Graphical abstract  
 
A Graphical abstract is optional and should summarize the contents of the article in a 
concise, pictorial form designed to capture the attention of a wide readership online. 
Authors must provide images that clearly represent the work described in the article. 
Graphical abstracts should be submitted as a separate file in the online submission system. 
Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or 
proportionally more. The image should be readable at a size of 5 × 13 cm using a regular 
screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. See 
http://www.elsevier.com/graphicalabstracts for examples.  
Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best 




Highlights are mandatory for this journal. They consist of a short collection of bullet points 
that convey the core findings of the article and should be submitted in a separate file in the 
online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet 
points (maximum 85 characters, including spaces, per bullet point). See 
http://www.elsevier.com/highlights for examples. 
 
Keywords  
Abbreviations should be held to a minimum and should appear only after the full length 
term has been spelled out once in the text. 
 
Acknowledgements  
Collate acknowledgements in a separate section at the end of the article before the references 
and do not, therefore, include them on the title page, as a footnote to the title or otherwise. 
List here those individuals who provided help during the research (e.g., providing language 
help, writing assistance or proof reading the article, etc.). 
 
Math formulae  
Present simple formulae in the line of normal text where possible and use the solidus (/) 
instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to 
be presented in italics. Powers of e are often more conveniently denoted by exp. Number 
consecutively any equations that have to be displayed separately from the text (if referred to 





Footnotes should be used sparingly. Number them consecutively throughout the article, 
using superscript Arabic numbers. Many wordprocessors build footnotes into the text, and 
this feature may be used. Should this not be the case, indicate the position of footnotes in the 
text and present the footnotes themselves separately at the end of the article. Do not include 
footnotes in the Reference list.  
Table footnotes  
Indicate each footnote in a table with a superscript lowercase letter. 
 
Artwork  
Electronic artwork  
General points  
• Make sure you use uniform lettering and sizing of your original artwork.  
• Save text in illustrations as 'graphics' or enclose the font.  
• Only use the following fonts in your illustrations: Arial, Courier, Times, Symbol.  
• Number the illustrations according to their sequence in the text.  
• Use a logical naming convention for your artwork files.  
• Provide captions to illustrations separately.  
• Produce images near to the desired size of the printed version.  
• Submit each figure as a separate file.  
 
A detailed guide on electronic artwork is available on our website:  
http://www.elsevier.com/artworkinstructions  
You are urged to visit this site; some excerpts from the detailed information are given 
here.  
Formats  
Regardless of the application used, when your electronic artwork is finalised, please 'save as' 
or convert the images to one of the following formats (note the resolution requirements for 
line drawings, halftones, and line/halftone combinations given below):  
EPS: Vector drawings. Embed the font or save the text as 'graphics'.  
TIFF: Color or grayscale photographs (halftones): always use a minimum of 300 dpi.  
TIFF: Bitmapped line drawings: use a minimum of 1000 dpi.  
TIFF: Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is 
required.  
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, 
Excel) then please supply 'as is'.  
132 
 
Please do not:  
• Supply files that are optimised for screen use (e.g., GIF, BMP, PICT, WPG); the resolution 
is too low;  
• Supply files that are too low in resolution;  
• Submit graphics that are disproportionately large for the content. 
 
Color artwork  
Please make sure that artwork files are in an acceptable format (TIFF, EPS or MS Office files) 
and with the correct resolution. If, together with your accepted article, you submit usable 
color figures then Elsevier will ensure, at no additional charge, that these figures will appear 
in color on the Web (e.g., ScienceDirect and other sites) regardless of whether or not these 
illustrations are reproduced in color in the printed version. For color reproduction in print, 
you will receive information regarding the costs from Elsevier after receipt of your 
accepted article. Please indicate your preference for color: in print or on the Web only. For 
further information on the preparation of electronic artwork, please see 
http://www.elsevier.com/artworkinstructions.  
Please note: Because of technical complications which can arise by converting color figures 
to 'gray scale' (for the printed version should you not opt for color in print) please submit in 
addition usable black and white versions of all the color illustrations. 
 
Figure captions  
Ensure that each illustration has a caption. Supply captions separately, not attached to the 
figure. A caption should comprise a brief title (not on the figure itself) and a description of 
the illustration. Keep text in the illustrations themselves to a minimum but explain all 
symbols and abbreviations used. 
 
Tables  
Number tables consecutively in accordance with their appearance in the text. Place footnotes 
to tables below the table body and indicate them with superscript lowercase letters. Avoid 
vertical rules. Be sparing in the use of tables and ensure that the data presented in tables do 
not duplicate results described elsewhere in the article. 
 
References  
Citation in text  
Please ensure that every reference cited in the text is also present in the reference list (and 
vice versa). Any references cited in the abstract must be given in full. Unpublished results 
and personal communications are not recommended in the reference list, but may be 
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mentioned in the text. If these references are included in the reference list they should follow 
the standard reference style of the journal and should include a substitution of the 
publication date with either 'Unpublished results' or 'Personal communication'. Citation of a 
reference as 'in press' implies that the item has been accepted for publication. 
 
Web references  
As a minimum, the full URL should be given and the date when the reference was last 
accessed. Any further information, if known (DOI, author names, dates, reference to a source 
publication, etc.), should also be given. Web references can be listed separately (e.g., after the 
reference list) under a different heading if desired, or can be included in the reference list. 
 
References in a special issue  
Please ensure that the words 'this issue' are added to any references in the list (and any 
citations in the text) to other articles in the same Special Issue. 
 
Reference management software  
This journal has standard templates available in key reference management packages 
EndNote (  http://www.endnote.com/support/enstyles.asp) and Reference Manager (  
http://refman.com/support/rmstyles.asp). Using plug-ins to wordprocessing packages, 
authors only need to select the appropriate journal template when preparing their article and 
the list of references and citations to these will be formatted according to the journal style 
which is described below. 
 
Reference style  
Text: Citations in the text should follow the referencing style used by the American 
Psychological Association. You are referred to the Publication Manual of the American 
Psychological Association, Sixth Edition, ISBN 978-1-4338-0561-5, copies of which may be 
ordered from http://books.apa.org/books.cfm?id=4200067 or APA Order Dept., P.O.B. 
2710, Hyattsville, MD 20784, USA or APA, 3 Henrietta Street, London, WC3E 8LU, UK. 
Details concerning this referencing style can also be found at 
http://linguistics.byu.edu/faculty/henrichsenl/apa/apa01.html. 
List: references should be arranged first alphabetically and then further sorted 
chronologically if necessary. More than one reference from the same author(s) in the same 
year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of publication.  
Examples:  
Reference to a journal publication:  
Van der Geer, J., Hanraads, J. A. J., & Lupton, R. A. (2010). The art of writing a scientific 
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article. Journal of Scientific Communications, 163, 51–59.  
Reference to a book:  
Strunk, W., Jr., & White, E. B. (2000). The elements of style. (4th ed.). New York: Longman, 
(Chapter 4).  
Reference to a chapter in an edited book:  
Mettam, G. R., & Adams, L. B. (2009). How to prepare an electronic version of your article. In 
B. S. Jones, & R. Z. Smith (Eds.), Introduction to the electronic age (pp. 281–304). New York: E-
Publishing Inc. 
 
Video data  
Elsevier accepts video material and animation sequences to support and enhance your 
scientific research. Authors who have video or animation files that they wish to submit with 
their article are strongly encouraged to include these within the body of the article. This can 
be done in the same way as a figure or table by referring to the video or animation content 
and noting in the body text where it should be placed. All submitted files should be properly 
labeled so that they directly relate to the video file's content. In order to ensure that your 
video or animation material is directly usable, please provide the files in one of our 
recommended file formats with a preferred maximum size of 50 MB. Video and animation 
files supplied will be published online in the electronic version of your article in Elsevier 
Web products, including ScienceDirect: http://www.sciencedirect.com. Please supply 
'stills' with your files: you can choose any frame from the video or animation or make a 
separate image. These will be used instead of standard icons and will personalize the link to 
your video data. For more detailed instructions please visit our video instruction pages at 
http://www.elsevier.com/artworkinstructions. Note: since video and animation cannot be 
embedded in the print version of the journal, please provide text for both the electronic and 
the print version for the portions of the article that refer to this content. 
 
Supplementary data  
Elsevier accepts electronic supplementary material to support and enhance your scientific 
research. Supplementary files offer the author additional possibilities to publish supporting 
applications, high-resolution images, background datasets, sound clips and more. 
Supplementary files supplied will be published online alongside the electronic version of 
your article in Elsevier Web products, including ScienceDirect: 
http://www.sciencedirect.com. In order to ensure that your submitted material is directly 
usable, please provide the data in one of our recommended file formats. Authors should 
submit the material in electronic format together with the article and supply a concise and 
descriptive caption for each file. For more detailed instructions please visit our artwork 
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instruction pages at http://www.elsevier.com/artworkinstructions. 
 
Submission checklist  
The following list will be useful during the final checking of an article prior to sending it to 
the journal for review. Please consult this Guide for Authors for further details of any item.  
Ensure that the following items are present:  
One author has been designated as the corresponding author with contact details:  
• E-mail address  
• Full postal address  
• Telephone and fax numbers  
All necessary files have been uploaded, and contain:  
• Keywords  
• All figure captions  
• All tables (including title, description, footnotes)  
Further considerations  
• Manuscript has been 'spell-checked' and 'grammar-checked'  
• References are in the correct format for this journal  
• All references mentioned in the Reference list are cited in the text, and vice versa  
• Permission has been obtained for use of copyrighted material from other sources 
(including the Web)  
• Color figures are clearly marked as being intended for color reproduction on the Web (free 
of charge) and in print, or to be reproduced in color on the Web (free of charge) and in black-
and-white in print  
• If only color on the Web is required, black-and-white versions of the figures are also 
supplied for printing purposes  
For any further information please visit our customer support site at 
http://support.elsevier.com. 
 
Additional information  
The word retarded should be used as an adjective rather than a noun; retardate should be 
avoided. Terms that are scientifically precise should be adhered to. Therefore, mentally 
retarded will be preferred to retarded because it specifies the type of retardation, and 
intellectually average or normal intelligence will be preferred over normal. A similar format 
should be followed if other disabilities are involved. It is understood that all investigations 




Appendix 2: Search strategy 
 
Table 1. Search strategy 
 
Source Search Strategy Results Hits 
NICE / SIGN 
Guidelines 
Down Syndrome, Aging, 
Memory 
NICE = 7 
SIGN = 0 
NICE = 0 














to July 02) 
 
1. (Cognit* or Memory).mp 
2. exp Neuropsychological Tests/ 
3. 1 or 2 
4. exp Down Syndrome/ 
5. 3 and 4 
6. exp Aging/ 
7. 5 and 6 
8. limit 7 to ("young adult and 
adult (19-24 and 19-44)" or 
"middle age (45 to 64 years)" or 
"middle aged (45 plus years)" 
or "all aged (65 and over)" or 





to 2012 July 02)  
 
 
1. (Cognit* or Memory).mp 
2. exp Neuropsychological Tests/ 
3. 1 or 2 
4. exp Down Syndrome/ 
5. 3 and 4 
6. exp Aging/ 
7. 5 and 6 
8.  limit 7 to (adult < 18 to 64 




Source Search Strategy Results Hits 
Cinahl 
(EBSCOhost) 
S1. Cognit* or memory 
S2. (MH*Neuropsychological 
Tests) 
S3. (MH*Down Syndrome) 
S4. (MH*Aging) 
S5. (MH*Age Factors) 
S6. S4 or S5  
S7. S1 or S2 
S8. S3 and S6 and S7  
S9. Narrow by SubjectAge: - 
Aged:  65+ years;  Middle Aged: 






S1. Cognit* or memory 
S2. MM*Neuropsychological 
Assessment 
S3. MM*Down’s Syndrome 
S4. MM*Aging 
S5. DE*Age Differences 
S6. S4 or S5  
S7. S1 or S2 
S8. S3 and S6 and S7  
S9. Narrow by SubjectAge: - 
Young Adulthood (18-29 yrs); 
Aged (65 yrs & older); Thirties 
(30-39 yrs);  
Middle Age (40-64 yrs); 
Adulthood (18 yrs & older)  
 
56 2 
ASSIA Descriptors: “down’s syndrome” 
AND (memory or cognit* or 
Neuropsychological Tests) 




Google Scholar down* syndrome (memory or 
cognit*) aging 
19,000 0 





Table 2. Reference search of included articles 
Reference Search Article Results Hits 
Web of Knowledge 
/ Web of Science 
(1945-Week 
beginning July 2nd 
2012) – Reference 
Search 
Caltagirone et al. 
(1990) 
4 0 
Carr (2003) 16 0 
Carr (2012) 0 0 
Das et al. (1995a) 16 0 
Das et al. (1995b) 21 0 
Devenny et al. 1992 18 0 (duplicates Carr, 
2003; Krinsky-
McHale et al. 2003) 




Krinsky-McHale et al. 
(2003) 
8 0 



















Table 3. Checklist for assessing the quality of included studies. Adapted from SIGN 
Guidelines 
 











B. Question(s) appropriate and 
adequately focussed 
Adequate (2) 
C. Question(s) inappropriate and 
poorly focussed 
Poor (1) 
D. Question(s) not addressed, not 
reported or not applicable. 
N/A (0) 
2. Comparison  / 
control group 
employed  
A. Groups are well matched  Well covered 
(3) 
B. Groups are adequately matched  Adequate (2) 
C. Group are poorly matched  Poor (1) 
D. No comparison group, matching 
not reported  
N/A (0) 





gical test(s) of 
memory. 
 
A. Test(s) employed have all 




B. Test(s) employed have 
demonstrated adequate 
reliability and validity. 
Adequate (2) 
C. Test(s) employed have 
demonstrated poor reliability 
and validity. 
Poor (1) 
D. Test(s) have not demonstrated 
reliability or validity. 
N/A (0) 








B. At least half of the tests 




Checklist Questions Quality Criteria 
neuropsycholo




reliability and validity. 
C. Less than half of the tests have 
demonstrated reliability and 
validity. 
Poor (1) 
D. None of the tests demonstrated 
reliability or validity. 
N/A (0) 





A. Tests were very appropriate for 




B. Tests were adequate for cognitive 
function being assessed. 
Adequate (2) 
C. Tests were poor for cognitive 
function being assessed. 
Poor (1) 
D. Tests were inappropriate for 












A. Test was appropriate and 




B. Test was appropriate and 
demonstrated adequate 
reliability / validity. 
Adequate (2) 
C. Test was appropriate and 
demonstrated poor reliability / 
validity. 
Poor (1) 
D. IQ test not addressed, not 
reported / not applicable. 
N/A (0) 










A. Memory problems / dementia 




B. Memory problems / dementia 
adequately assessed at 
enrolement and adequately 
addressed throughout. 
Adequate (2) 
C. Memory problems / dementia 
poorly assessed at enrolement 




Checklist Questions Quality Criteria 
throughout. 
D. Memory problems / dementia not 
assessed at enrolement or 
addressed throughout. 
N/A (0) 













B. Other cognitive functions 
adequately assessed. 
Adequate (2) 
C. Other cognitive functions poorly 
assessed. 
Poor (1) 
D. Other cognitive functions not 
assessed. 
N/A (0) 









C. Statistics appropriate and 
adequately reported. 
Adequate (2) 
D. Statistics appropriate but poorly 
reported. 
Poor (1) 
E. Statistics inappropriate, not 
clearly reported or not 
applicable. 
N/A (0) 
10. Effect sizes 
reported. 
A. Effect sizes reported. Yes (1) 














Appendix 4: Summary of Quality Rating of Included Papers   
 














































































































1. Appropriate & clear 
question 
3 3 3 1 1 0 0 2 
2. Comparison / Control 
Group 
1 1 2 1 0 0 1 1 
3. Memory 2 2 2 1 2 2 1 1 
4. Other tests of 
cognition 
3 3 0 1 0 0 1 0 
5. Appropriate tests  3 3 3 3 3 3 2 2 
6. IQ Test  2 0 0 1 2 2 0 0 
7. Dementia addressed 1 0 2 1 2 2 2 2 
8. Other cognitive 
functions assessed 
2 2 0 1 0 0 1 0 
9. Statistics 3 3 3 3 3 3 2 1 
10. Effect size  0 0 1 0 0 0 0 0 
Total (28) 20 17 16 13 13 13 10 9 
 
Table 5 shows individual scores on each quality criteria. Longitudinal papers received less 
points on quality overall (9-13) (Carr, 2003, 2012; Devenny et al., 1992, 1996) than cross-
sectional papers (13-20) (Caltagirone et al., 1990; Das et al., 1995a, 1995b; Krinsky-McHale 










SUBMISSION OF MANUSCRIPTS 
 
Language: The language of publication is English. Authors for whom English is a second 
language must have their manuscript professionally edited by an English speaking person 
before submission to make sure the English is of high quality. It is preferred that 
manuscripts are professionally edited. A list of independent suppliers of editing services can 
be found at http://authorservices.wiley.com/bauthor/english_language.asp . All services are 
paid for and arranged by the author and use of one of these services does not guarantee 
acceptance or preference for publication. 
 
Abbreviations, Symbols and Nomenclature: Spelling should conform to The Concise 
Oxford Dictionary of Current English and units of measurements, symbols and 
abbreviations with those in Units, Symbols and Abbreviations (1977) published and 
supplied by the Royal Society of Medicine, 1 Wimpole Street, London W1M 8AE. This 
specifies the use of SI units. 
 
It is important that the term 'intellectual disabilities' is used when preparing manuscripts. 
 
Please note that 'intellectual disability', as used in the Journal, includes those conditions 





All manuscripts submitted to The Journal of Intellectual Disability Research should include: 
Title, Keywords, structured Abstract, Main Text (divided by appropriate sub headings) and 
References. 
 
Title Page: Please remember that peer-review is double-blind, so that neither authors nor 
reviewers know each others' identity. Therefore, no identifying details of the authors or 
their institutions must appear in the submitted manuscript; author details should be 
entered as part of the online submission process. However, a 'Title Page' must be 
submitted as part of the submission process as a 'Supplementary File Not for Review'. This 
should contain the title of the paper, names and qualifications of all authors, their affiliations 




Keywords: The author should also provide up to six keywords to aid indexing. 
 
Abstracts: For full and brief reports a structured summary should be included at the 
beginning of each article, incorporating the following headings: Background, Method, 
Results, and Conclusions. These should outline the questions investigated, the design, 
essential findings, and the main conclusions of the study. 
 
Optimizing Your Abstract for Search Engines: Many students and researchers looking for 
information online will use search engines such as Google, Yahoo or similar. By optimizing 
your article for search engines, you will increase the chance of someone finding it. This in 
turn will make it more likely to be viewed and/or cited in another work. We have compiled 




The Journal follows the Harvard reference style. References in text with more than two 
authors should be abbreviated to (Brown et al. 1977). Authors are responsible for the 
accuracy of their references. 
 
The reference list should be in alphabetical order thus: 
 Giblett E.R. (1969) Genetic Markers in Human Blood. Blackwell Scientific 
Publications, Oxford. 
 Moss T.J. & Austin G.E. (1980) Preatherosclerotic lesions in Down's syndrome. 
Journal of Mental Deficiency Research 24, 137- 41. 
 Seltzer M. M. & Krauss M.W. (1994) Aging parents with co-resident adult children: 
the impact of lifelong caregiving. In: Life Course Perspectives on Adulthood and Old 
Age (eds M. M. Seltzer, M.W. Krauss & M. P. Janicki), pp. 3-18. American 
Association on Mental Retardation, Washington, DC. 
Where more than six authors are listed for a reference please use the first six then 'et al.' 
 
The Editor and Publisher recommend that citation of online published papers and other 
material should be done via a DOI (digital object identifier), which all reputable online 
published material should have - see www.doi.org/ for more information. If an author cites 
anything which does not have a DOI they run the risk of the cited material not being 
traceable. 
 
We recommend the use of a tool such as EndNote or Reference Manager for reference 
management and formatting. 
 
EndNote reference styles can be searched for here: www.endnote.com/support/enstyles.asp 
Reference Manager reference styles can be searched for here: 
www.refman.com/support/rmstyles.asp 
 
Tables, Figures and Figure Legends 
Tables: Tables should include only essential data. Each table must be typewritten on a 
separate sheet and should be numbered consecutively with Arabic numerals, e.g. Table 1, 
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Table 2, etc., and given a short caption. 
 
Figures: All graphs, drawings and photographs are considered figures and should be 
numbered in sequence with Arabic numerals. All symbols and abbreviations should be 
clearly explained. 
 
Tables and figures should be referred to in the text together with an indication of their 
approximate position recorded in the text margin. 
 
Preparation of Electronic Figures for Publication 
Although low quality images are adequate for review purposes, print publication requires 
high quality images to prevent the final product being blurred or fuzzy. Submit EPS (line 
art) or TIFF (halftone/photographs) files only. MS PowerPoint and Word Graphics are 
unsuitable for printed pictures. Do not use pixel-oriented programmes. Scans (TIFF only) 
should have a resolution of at least 300 dpi (halftone) or 600 to 1200 dpi (line drawings) in 
relation to the reproduction size (see below). Please submit the data for figures in black and 
white or submit a Colour Work Agreement Form (see Colour Charges below). EPS files 
should be saved with fonts embedded (and with a TIFF preview if possible). 
 
For scanned images, the scanning resolution (at final image size) should be as follows to 
ensure good reproduction: line art: >600 dpi; halftones (including gel photographs): >300 
dpi; figures containing both halftone and line images: >600 dpi. 
 
Further information can be obtained at Wiley-Blackwell's guidelines for figures: 
http://authorservices.wiley.com/bauthor/illustration.asp 
 
Check your electronic artwork before submitting it: 
http://authorservices.wiley.com/bauthor/eachecklist.asp 
 
Permissions: If all or parts of previously published illustrations are used, permission must 
be obtained from the copyright holder concerned. It is the author's responsibility to obtain 
these in writing and provide copies to the Publisher. 
 
Colour Charges: It is the policy of The Journal of Intellectual Disability Research for authors to 
pay the full cost for the reproduction of their colour artwork. Therefore, please note that if 
there is colour artwork in your manuscript when it is accepted for publication, 
 
Wiley-Blackwell require you to complete and return a Colour Work Agreement Form before 
your paper can be published. Any article received by Wiley-Blackwell with colour work will 
not be published until the form has been returned. If you are unable to access the internet, or 
are unable to download the form, please contact the Production Editor (jir@wiley.com) 
 


















































































Appendix 9: Participant information sheet  






MEMORY AND LEARNING DISABILITIES 
 
PARTICIPANT INFORMATION SHEET 
 
We would like to invite you to take part in a research study. The aim of the study is to find 
better ways to assess people’s memory. The information sheet tells you about the study. 
Please read the information sheet, or ask someone to read it with you. This information 
sheet is for you to keep.  
 
You can talk to your family and friends about the study. Ask them what they think about it.  
 
 
What is the research study about? 
The aim is to see if we can assess memory using a tool called the Visual Association Test 
(VAT). 
 
The VAT is helpful in assessing memory in adults and in older people. We want to see if the 
VAT is helpful for assessing memory in people with a learning disability. 
 
Having good tests for memory can help us tell if there are any problems we can help with.   
 
Our memory helps us to remember: 
 
 people’s names 
 names of objects 
 things that we have done in the past 
 
Why do you want me to take part? 
We are inviting you to take part because you are using the learning disabilities services. A 
staff member who knows you thinks you might be interested in taking part.  
 
What will the research study involve? 
If you want to find out more the researcher will contact you and ask to visit you.  You do not 
have to meet the researcher. The researcher is a Trainee Clinical Psychologist and will be 
supervised by a qualified Clinical Psychologist.  
 
You can ask the researcher questions about the study.  The researcher will ask you to 
decide if you want to take part in the research study.  If you say yes, you will be asked to 
sign a consent form.  You can keep a copy of the form.  
 
If you choose to take part, the researcher will visit you again. The meetings will be at a place 




The researcher will do some tests with you. This will involve showing you pictures of objects 
and asking you to name them. The researcher may ask you to do other tasks and ask 
questions about words and numbers.  
 
We would like to look at your medical file to check if you have any physical problems which 
may affect your memory. We would also like to look at your psychology file to see if you have 
completed any of these tests before.  
 
We will ask you if we can tell your GP that you are taking part in the study. 
 
What if there is a problem? 
If you have a concern about the study, you should ask to speak to the researcher. The 
researcher will do their best to answer your questions. If you would like to speak to someone 
else about this study you can call NAME, TELEPHONE NUMBER. 
 
If you wish to complain about any aspect of the way you have been treated during the course 
of this study, the normal National Health Service complaints mechanism will still be available 
to you. 
 
Has ethical approval been granted for this study? 
This study has been granted ethical approval by the Scotland A Research Ethics Committee. 
 
When will the study take place? 
This study will take place during 2012. You will meet the researcher on a maximum of three 
appointments.  
 
Will taking part in the study help me? 
Taking part might not help you directly. Nobody has used this test before with people with 
learning disabilities.  
 
The results of this study may help us in the future to test other people’s memory.  
 
What will happen if I decide not to take part in the study? 
You do not have to take part in this research study.  It is OK to say no.  If you don’t want to 
take part, this will not affect the care and support you receive. 
 
What if I change my mind and do not want to take part during the study? 
You can change your mind about taking part, or stop, at any time.  You do not have to give a 
reason.  If you change your mind this will not affect the care and support you receive.  
 
Where would the interviews take place? 
If it is OK with you, the researcher will arrange to see you at either your home or at a clinic if 
you prefer.  If you want the researcher can arrange to see you somewhere else.  
 
What will happen to the information the researcher collects? 
All the information about you is kept safe. It will be treated with strict confidence. It will be 
kept secret. The researcher will not tell anyone your name. The information will be kept 
safely on a computer. The Data Protection Act will be followed at all times. 
 
What will happen to the results of the study? 
When the research study is finished, the researcher will write to you about the research 
findings. They will also write reports about the research. Your name will not be used in the 
reports. No one will be able to tell from the reports if you took part in the research. 
 
Who is organising and funding the research? 
This study is part of the researcher’s Doctorate in Clinical Psychology qualification. The 





How can I find out more about the study? 
You can ask the researcher questions about the study.  The name and telephone number of 
the researcher is shown below.  You can contact her at any time to ask questions. 
 
You might like to speak to someone else about the research. NAME SURNAME can be 
contacted on the telephone. His number is XXXXX. NAME will try and answer any questions 
you have. 
 














What do I do now? 
It is up to you to choose whether you want to take part in the study. Let us know if you want 
to find out more about the study by ticking one of the boxes.  
 
If you tick the YES box the researcher will contact you.   YES 
 
 

























Appendix 10: Staff information sheet 
 
Staff Information Sheet 
 
Study Title: The clinical utility of the Visual Association Test (VAT) in adults with 
Intellectual Disabilities 
Your patient is being invited to take part in a research study. It is important for you to 
understand why the research is being carried out and what it will involve.  
 
Why are we doing this research? 
This research project is examining the utility of the Visual Association Test (VAT) in adults 
with intellectual disabilities. The VAT is a neuropsychological test of associative memory. The 
project is hoping to find out how adults with intellectual disabilities perform on this test and 
whether it could be used as a clinical tool in the future. 
 
Why have they been invited to take part? 
Your patient has been invited to take part as they have an intellectual disability. The study 
aims to include 44 people between 18 and 45 years of age.  
 
Do they have to take part?  
It is up to the person whether they consent to taking part. If they decide to take part they are 
free to change their mind at any time during the study without giving a reason. A decision to 
withdraw from the study or not to take part will not affect their standard of care. 
 
What is involved? 
Your patient will be seen by Ann McPaul, Trainee Clinical Psychologist to assess whether 
they have the capacity to consent to the research. If they can consent and do wish to take 
part, Ann will arrange to see them again at an agreed time at their home or at a clinic nearby. 
The patient will be asked to complete some assessments of their memory and cognitive 
abilities. This may take between one to two hours to complete, breaks will be provided and 
the assessment may be completed over one or two sessions.  
 
Is there any harm to participating in this research? 
The tasks and assessments used in this study will not cause them any harm. However, if you 
were to have any concerns, Ann McPaul would discuss these with you. 
 
How is this research useful? 
Taking part does not have direct benefits or disadvantages. However, the information we get 
from this study may help us to learn more about the utility of this test in assessing memory in 
people with intellectual disabilities. In the long-term, this may help us in screening for 








 Date  
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What if there is a problem? 
If you have a concern about any aspect of the study, you should ask to speak to Ann 
McPaul, who will do her best to answer your questions. If you would like to speak to an 
independent person about this study you may also contact NAME, DESIGNATION, 
TELEPHONE NUMBER who will answer any queries you may have relating to this research. 
 
If you wish to complain formally regarding your treatment during you participation in the 
research, you can do this through the organisations Complaints Procedure. Details of this 
can be obtained from the hospital. The normal National Health Service complaints 
mechanism will still be available to you. 
 
What will happen to the results of the research study? 
Your patient can choose to have a summary of the results emailed or posted to them after 
the end of the study in August 2012. The results of this study may be published in a scientific 
journal and if so, will be published one to two years after the end of the study. It will not be 
possible to identify participants in any of these reports. 
 
Will my taking part in this research be kept confidential? 
All information which is collected about the patient during the course of the research will be 
kept strictly confidential. Only members of the research team will have access to this 
information. Any information about your patient will have their name and address removed so 
that they cannot be recognised from it.  
 
With their permission we will inform their General Practitioner of their participation in this 
study. In the unlikely event that participation uncovers a problem, we will also seek their 
permission to inform their GP. 
 
We will also ask their permission to access their medical file for further information about any 
medical conditions which may impact on testing. In addition, we will ask for permission to 
access their psychology file to see if they have completed a WAIS-IV assessment and if so, 
this will not be repeated. 
 
Who is organising and funding the research? 
This study is part of the researcher’s Doctorate in Clinical Psychology qualification. This 
research is being funded by the University of Edinburgh. 
 
Who has reviewed the study? 
All research is looked at by an independent group of people, called a Research Ethics 
Committee to protect your patient’s safety, rights, wellbeing and dignity. This research has 
been reviewed by an NHS ethics committee. 
 
Who do I contact for further information? 
If you would like any more information about this study, please contact Ann McPaul (Trainee 
Clinical Psychologist) on XXXX. Alternatively, if you would like to speak to an independent 
person about this study, please contact NAME, DESIGNATION, TELEPHONE NUMBER. 
 
 
















MEMORY AND LEARNING DISABILITIES 
 
PARTICIPANT CONSENT FORM 
 
This form asks if I will take part in a research study. 
 
A researcher will ask me questions about my memory. 
 
The researcher will keep my information confidential (secret) and safe. 
 
 
Please tick the box if you agree with what it says. 
 
I have been given an information sheet about the study  YES 
     
       
I have asked all the questions I want to    YES     
 
 
I have been given enough answers to my questions.  YES 
   
          
I know it is OK to say ‘No’ to taking part in the study.   YES 
I don’t have to take part. I don’t have to say why.      
  
   
Saying ‘No’ will not affect my care or support in any way.  YES               
  
              
I know I can change my mind and say ‘No’ later on.  YES    
 
           
I know the researcher will write about the study results.     YES 
 
 
I know the results will not include my name.  No one will   YES 
be able to identify me from the results.  
    
 
The researcher will let my GP know I am taking part.                 YES 
   
 
I consent to my medical and psychology file being accessed  YES 




I know that relevant sections of my medical notes and data  YES 
collected in this study may be looked at by the regulatory  
authorities, sponser or NHS organisation.  
 
 
I agree to taking part in the research study     YES 
            
Participant signature of consent 
Signed ……………………………………………………………………………… 
Name ……………………………………………………………………………….. 
Date ………………………………………………………………………………… 
 
Witness signature 
Signed……………………………………………………………………………… 
Name ..…………………………………………………………………………….. 
Date ………………………………………………………………………………… 
 
 
Researcher  
 
NAME 
ADDRESS 
TELEPHONE 
 
 
 
 
 
Researcher signature 
 
Signed………………………………………………………………………………. 
Name………………………………………………………………………………… 
Date …………………………………………………………………………………. 
 
 
 
 
 
 
Researcher’s 
Photo 
